Compounds and methods for modulating angiotensinogen expression
Patent Information
- Application Number
- JP2023529940
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-08-11
- Filing Date
- 2021-11-18
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-11-18
AI Technical Summary
Current treatments for hypertension, particularly those targeting the renin-angiotensin-aldosterone system (RAAS), have limitations in inhibiting the RAAS pathway and are not effective for all hypertensive patients, especially those with renal disease, necessitating the development of alternative therapies.
Development of compounds and pharmaceutical compositions that reduce angiotensinogen (AGT) RNA and protein expression using modified oligonucleotides, including oligomeric compounds with modified sugar moieties and internucleoside linkages, to modulate the RAAS pathway and treat hypertension and related diseases.
These compounds effectively reduce AGT activity, providing therapeutic benefits for hypertension and associated conditions such as resistant hypertension, heart failure, and kidney disease, offering a more comprehensive approach than existing treatments.
Smart Images

Figure 2022109139000001 
Figure 2022109139000002 
Figure 2022109139000003
Abstract
Description
[Technical Field]
[0001] Sequence List This application is filed electronically along with a sequence listing. The sequence listing is provided as a file named BIOL0393WOSEQ_ST25.txt, created on November 3, 2021, with a size of 32KB. The electronic information of this sequence listing is incorporated herein by reference in its entirety.
[0002] Compounds, methods, and pharmaceutical compositions are provided for reducing the amount or activity of angiotensinogen RNA in cells or subjects, and, in certain cases, for reducing the amount of angiotensinogen (AGT) in cells or subjects. Such compounds and pharmaceutical compositions are useful for improving at least one symptom or feature of RAAS pathway-related diseases or disorders. Such diseases and disorders include hypertension, hypertensive emergencies (i.e., malignant hypertension), resistant hypertension, kidney disease (e.g., chronic kidney disease, polycystic kidney disease), pre-eclampsia, Marfan syndrome, stroke, heart disease (e.g., myocardial infarction, heart failure, congestive heart failure, valvular heart disease), vascular aneurysms, abdominal aneurysms, peripheral artery disease, organ injury, pulmonary hypertension, obesity, metabolic syndrome, NASH, NAFLD, and other RAAS-related diseases, disorders and / or conditions, or their symptoms. [Background technology]
[0003] Angiotensinogen (AGT), also known as SERPINA8 or ANHU, is a member of the serpine family and a component of the renin-angiotensin-aldosterone system (RAAS). It is primarily produced in the liver and released into circulation, where renin converts it to angiotensin I. Angiotensin I is then converted to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II is a peptide hormone that causes vasoconstriction and can raise blood pressure. Angiotensin II also stimulates the secretion of the hormone aldosterone from the adrenal cortex. Aldosterone can increase the reabsorption of sodium and water by the kidneys, increasing the volume of body fluids and potentially raising blood pressure. Stimulation or excessive activity of the RAAS pathway can lead to hypertension. Chronic hypertension is known as hypertension. Hypertension, as defined by hypertension, requires the heart to work harder to circulate blood through the blood vessels.
[0004] Hypertension remains a leading cause of death and disability worldwide due to cardiovascular disease and stroke. Despite extensive research and the existence of multiple effective treatments, hypertension remains a significant public health challenge in the United States (Sigmund et al., Hypertension 2020, 75:902-917). Currently approved treatments for hypertension have limitations, and a significant portion of all hypertensive patients do not achieve adequate blood pressure control. For example, drugs such as ACE inhibitors and angiotensin receptor blockers (ARBs) that target parts of the renin-angiotensin system (RAS) pathway have limited ability to inhibit the RAAS pathway (Nobakht et al., Nat Rev Nephrol, 2011, 7:356-359). Furthermore, certain antihypertensive drugs, such as ACE inhibitors, can impair renal function and are therefore contraindicated in hypertensive patients with renal disease.
[0005] Therefore, it is necessary to find alternative therapies to inhibit the RAAS pathway and treat hypertension. Accordingly, it is the object of this specification to provide compounds, methods, and pharmaceutical compositions for treating such diseases. [Overview of the Initiative]
[0006] Compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA and, in certain embodiments, reducing the expression of AGT protein in cells or subjects are provided herein. In certain embodiments, the subjects have cardiovascular disease. In certain embodiments, the subjects have hypertension. In certain embodiments, the subjects have resistant hypertension. In certain embodiments, the subjects have Marfan syndrome. In certain embodiments, the subjects have kidney disease. In certain embodiments, the compounds useful for reducing the amount or activity of AGT RNA are oligomeric compounds. In certain embodiments, the compounds useful for reducing the amount or activity of AGT RNA are modified oligonucleotides. In certain embodiments, the compounds useful for reducing the expression of AGT protein are oligomeric compounds. In certain embodiments, the compounds useful for reducing the expression of AGT protein are modified oligonucleotides.
[0007] Methods useful for improving at least one symptom or feature of an RAAS pathway-related disease or indication are also provided. In certain embodiments, the disease is hypertension. In certain embodiments, the disease is resistant hypertension. In certain embodiments, the disease is Marfan syndrome. In certain embodiments, the indication is heart failure. In certain embodiments, symptoms or features include hypertension, hypertensive emergencies (i.e., malignant hypertension), pre-eclampsia, stroke, heart disease (e.g., myocardial infarction, heart failure, congestive heart failure, valvular heart disease), vascular aneurysms, abdominal aneurysms, organ injury, pulmonary hypertension, obesity, and other RAAS pathway-related diseases, disorders, and / or conditions or their symptoms. [Modes for carrying out the invention]
[0008] Please understand that the above summary and the following detailed explanation are illustrative and descriptive only, and not limiting. In this specification, the use of the singular includes the plural unless otherwise explicitly stated. Where used herein, the use of "or" means "and / or" unless otherwise explicitly stated. Furthermore, the use of the term "contains," as well as other forms such as "contains" and "includes," is not limiting. Also, terms such as "element" or "component" include both elements and components containing one unit, and elements and components containing two or more subunits, unless otherwise explicitly stated.
[0009] The headings of sections used herein are for structural purposes only and should not be construed as limiting the subject matter described herein. All documents or parts of documents listed in this application, including but not limited to patents, patent applications, articles, books, papers, and GenBank, ENSEMBL, and NCBI reference sequencing records, as well as parts of documents considered herein, and all of them, are expressly incorporated herein by reference.
[0010] definition Unless otherwise specified, the nomenclature, procedures, and techniques used in relation to analytical chemistry, organic synthesis chemistry, and pharmaceutical and drug discovery chemistry described herein are well known and commonly used in the art. Where permitted, all patents, applications, published applications, and other publications and data referenced throughout this disclosure are incorporated herein by reference in their entirety.
[0011] Unless otherwise specified, the following terms have the meanings described below.
[0012] definition As used herein, “2'-deoxynucleoside” means a nucleoside containing a 2'-H(H)deoxyfuranosyl sugar moiety. In certain embodiments, the 2'-deoxynucleoside is a 2'-β-D-deoxynucleoside containing a 2'-β-D-deoxyribosyl sugar moiety having a β-D configuration similar to that found in naturally occurring deoxyribonucleic acid (DNA). In certain embodiments, the 2'-deoxynucleoside may contain a modified nucleic acid base or an RNA nucleic acid base (uracil).
[0013] As used herein, "2'-MOE" means a 2'-OCH2CH2OCH3 group instead of the 2'-OH group in the furanosyl sugar moiety. "2'-MOE sugar moiety" means a sugar moiety having a 2'-OCH2CH2OCH3 group instead of the 2'-OH group in the furanosyl sugar moiety. Unless otherwise indicated, the 2'-MOE sugar moiety is in a β-D-ribosyl configuration. "MOE" means O-methoxyethyl.
[0014] As used herein, "2'-MOE nucleoside" means a nucleoside containing a 2'-MOE sugar moiety.
[0015] As used herein, "2'-OMe" means a 2'-OCH3 group instead of a 2'-OH group in the furanosyl sugar moiety. As used herein, "2'-O-methyl sugar moiety" or "2'-OMe sugar moiety" means a sugar moiety having a 2'-OCH3 group instead of a 2'-OH group in the furanosyl sugar moiety. Unless otherwise indicated, the 2'-OMe sugar moiety is in a β-D-ribosyl configuration.
[0016] As used herein, "2'-OMe nucleoside" means a nucleoside containing a 2'-OMe sugar moiety.
[0017] As used herein, “2'-substituted nucleoside” means a nucleoside containing a 2'-substituted sugar moiety. As used herein with respect to the sugar moiety, “2'-substituted” means a sugar moiety containing at least one 2'-substituent other than H or OH.
[0018] As used herein, "5-methylcytosine" means cytosine modified with a methyl group attached at the 5-position. 5-methylcytosine is a modified nucleic acid base.
[0019] Where used herein, "approximately" means within ±10% of the value. For example, if it is stated that "the compound resulted in approximately 70% inhibition of AGT," it implies that the AGT level was inhibited within a range of 63% to 77%.
[0020] As used herein, “administer” means to provide a pharmaceutical agent to the subject.
[0021] As used herein, “angiotensinogen” and “AGT” are used synonymously. Angiotensinogen is also known as SERPINA8 and ANHU.
[0022] As used herein, “antihypertensive agent” refers to a drug that can lower blood pressure. Examples of such drugs include, but are not limited to, RAAS inhibitors, diuretics, calcium channel blockers, adrenergic receptor antagonists, adrenergic agonists, and vasodilators. For example, the antihypertensive agent captopril can be used in combination with the AGT compounds described herein to treat animals that have, or are at risk of having, RAAS pathway-related diseases, disorders, and / or conditions.
[0023] As used herein, “antisense activity” means any detectable and / or measurable change that may result from the hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a reduction in the amount or expression of the target nucleic acid or the protein encoded by such target nucleic acid compared to the level of the target nucleic acid or the target protein in the absence of the antisense compound.
[0024] As used herein, “antisense compound” means an oligomeric compound or oligomeric double chain capable of achieving at least one antisense activity.
[0025] As used herein, “improvement” in relation to treatment means improvement in at least one symptom compared to the same symptom without treatment. In certain embodiments, improvement is a decrease in the severity or frequency of a symptom, or a delay in the onset of a symptom or a decrease in the rate of progression of its severity or frequency. The progression or severity of an indicator may be determined by subjective or objective measures, which are known to those skilled in the art.
[0026] As used herein, “blood pressure” refers to the pressure of blood in the circulatory system against the walls of blood vessels. In animals, blood pressure is primarily due to the beating of the heart. Between each heartbeat, blood pressure changes between the maximum (systolic) blood pressure (SBP) and the minimum (diastolic) blood pressure (DBP). Mean arterial pressure (MAP) is the mean arterial pressure during a heart cycle. Blood pressure can be measured by a blood pressure monitor (i.e., a blood pressure monitor). Normal resting blood pressure is less than 120 mmHg for systolic and less than 80 mmHg for diastolic, and is generally expressed as systolic blood pressure (upper blood pressure) / diastolic blood pressure (lower blood pressure) mmHg.
[0027] As used herein, “bicyclic nucleoside” or “BNA” means a nucleoside containing a bicyclic sugar moiety.
[0028] As used herein, “bicyclic sugar” or “bicyclic sugar moiety” means a modified sugar moiety comprising two rings, the second ring being formed via a bridge connecting two atoms in the first ring, thereby forming a bicyclic structure. In certain embodiments, the first ring of the bicyclic sugar moiety is a furanosyl moiety. In certain embodiments, the furanosyl sugar moiety is a ribosyl moiety. In certain embodiments, the bicyclic sugar moiety does not contain a furanosyl moiety.
[0029] As used herein, "cEt" means a 4'-to-2' bridge in place of the 2'OH group of the ribosyl sugar moiety, the bridge having the formula 4'-CH(CH3)-O-2', and the methyl group of the bridge being in the S configuration. "cEt sugar moiety" is a bicyclic sugar moiety having a 4'-to-2' bridge in place of the 2'OH group of the ribosyl sugar moiety, the bridge having the formula 4'-CH(CH3)-O-2', and the methyl group of the bridge being in the S configuration. "cEt" means constrained ethyl.
[0030] As used herein, "cEt nucleoside" means a nucleoside containing a cEt sugar moiety.
[0031] As used herein, “cleavable portion” means a bond or group of atoms that are cleaved under physiological conditions, for example, within a cell, subject, animal, or human.
[0032] As used herein, “complementary” in relation to oligonucleotides means that at least 70% of the nucleic acid bases of one or more parts of an oligonucleotide and the nucleic acid bases of one or more parts of another nucleic acid can form hydrogen bonds with each other when the nucleic acid base sequences of the oligonucleotide and another nucleic acid are aligned in opposite directions. As used herein, “complementary nucleic acid bases” means nucleic acid bases that can form hydrogen bonds with each other. Complementary nucleic acid base pairs include adenine (A) and thymine (T), adenine (A) and uracil (U), cytosine (C) and guanine (G), and 5-methylcytosine ( m(C) and guanine (G) are included. Complementary oligonucleotides and / or target nucleic acids do not need to have nucleic acid base complementarity at each nucleoside. Rather, some mismatches are acceptable. As used herein, “fully complementary” or “100% complementary” in relation to an oligonucleotide or part thereof means that the oligonucleotide or part thereof is complementary to another oligonucleotide or target nucleic acid at each nucleic acid base of the shorter of two oligonucleotides, or at each nucleoside if the oligonucleotides are of the same length.
[0033] As used herein, "conjugate group" means an atomic group directly or indirectly bonded to an oligonucleotide. A conjugate group includes a conjugate moiety and a conjugate linker that bonds the conjugate moiety to an oligonucleotide.
[0034] As used herein, “conjugate linker” means a group of atoms containing a single bond or at least one bond that links the conjugate portion to an oligonucleotide.
[0035] As used herein, “conjugate moiety” means the group of atoms bonded to an oligonucleotide via a conjugate linker.
[0036] As used herein, “consecutive” in the context of oligonucleotides means nucleosides, nucleic acid bases, sugar moieties, or internucleoside bonds that are directly adjacent to each other. For example, “consecutive nucleic acid bases” means nucleic acid bases that are directly adjacent to each other in sequence.
[0037] As used herein, “chiral-enriched population” means a group of molecules having the same molecular formula in which the number or percentage of molecules containing a particular stereochemical configuration at a particular chiral center is greater than the number or percentage of molecules in the population that would be expected to contain the same particular stereochemical configuration at the same particular chiral center if the particular chiral center were stereorandom. A chiral-enriched population of molecules having multiple chiral centers in each molecule may contain one or more stereorandom chiral centers. In certain embodiments, the molecule is a modified oligonucleotide. In certain embodiments, the molecule is a compound containing a modified oligonucleotide.
[0038] As used herein, "chiralally controlled" with respect to nucleoside bonds means that the chirality of those bonds is concentrated for a particular stereochemical configuration.
[0039] As used herein, “deoxy region” means a region of 5 to 12 consecutive nucleotides, where at least 70% of the nucleosides are 2'-β-D-deoxynucleosides. In certain embodiments, each nucleoside is selected from 2'-β-D-deoxynucleosides, bicyclic nucleosides, and 2'-substituted nucleosides. In certain embodiments, the deoxy region assists RNaseH activity. In certain embodiments, the deoxy region is a gap or internal region of a gapmer.
[0040] As used herein, “gapmer” means a modified oligonucleotide in which an internal region having multiple nucleosides that assist in RNaseH cleavage is located between an external region having one or more nucleosides, wherein the nucleosides constituting the internal region are chemically distinct from the nucleosides or multiple nucleosides constituting the external region. The internal region may be referred to as the “gap,” and the external region may be referred to as the “wing.” The internal region is a deoxy region. The position of the internal region or gap refers to the order of the nucleosides in the internal region, counted from the 5' end of the internal region. Unless otherwise indicated, “gapmer” means a sugar motif. In certain embodiments, each nucleoside in the gap is a 2'-β-D-deoxynucleoside. In certain embodiments, the gap contains one 2'-substituted nucleoside at position 1, 2, 3, 4, or 5 of the gap, and the remaining nucleosides in the gap are 2'-β-D-deoxynucleosides. As used herein, “MOE gapmer” refers to a gapmer having a gap containing a 2'-β-D-deoxynucleoside and a wing containing a 2'-MOE nucleoside. As used herein, the term “mixed-wing gapmer” refers to a gapmer having a wing containing a modified nucleoside having at least two different sugar modifications. Unless otherwise indicated, a gapmer may contain one or more modified nucleoside bonds and / or modified nucleic acid bases, and such modifications do not necessarily follow a gapmer pattern of sugar modifications.
[0041] As used herein, “hotspot region” refers to a range of nucleic acid bases on a target nucleic acid that is prone to oligomer compound-mediated reduction in the amount or activity of the target nucleic acid.
[0042] As used herein, “hybridization” means the pairing or annealing of complementary oligonucleotides and / or nucleic acids. While not limited to specific mechanisms, the most common mechanism of hybridization involves hydrogen bonding between complementary nucleic acid bases, which may be Watson-Crick, Hoogsteen, or inverse Hoogsteen hydrogen bonds.
[0043] As used herein, “hypertension” or “HTN” refers to a chronic medical condition in which blood pressure is elevated in animals. When blood pressure is high, the heart works harder to circulate blood through the blood vessels. Hypertension is said to be persistently present at 130 / 80 mmHg (stage 1) or 140 / 90 mmHg (stage 2) or higher. Hypertension is classified as primary (essential) or secondary. Primary hypertension has no clear cause and is thought to be associated with genetics, diet, lack of exercise, and obesity. Secondary hypertension is caused by another medical condition. Hypertension is a major risk factor for shortened life expectancy, chronic kidney disease, stroke, myocardial infarction, heart failure, aneurysms of blood vessels (e.g., aortic aneurysm), peripheral artery disease, organ damage (e.g., cardiac hypertrophy or hypertrophy), and other cardiovascular diseases, disorders, and / or conditions or their symptoms. Antihypertensive drugs, dietary changes, and lifestyle changes can reduce hypertension and alleviate hypertension-related illnesses, disorders, and / or conditions. Hypertension may be non-resistant to drug intervention (i.e., controllable with commercially available drug therapies) or resistant to drug intervention.
[0044] As used herein, the term “nucleoside bond” refers to a covalent bond between consecutive nucleosides in an oligonucleotide. As used herein, “modified nucleoside bond” means any nucleoside bond other than a phosphodiester nucleoside bond. “Phosphothioate nucleoside bond” refers to a modified nucleoside bond in which one of the non-bridged oxygen atoms of a phosphodiester nucleoside bond is replaced with a sulfur atom.
[0045] As used herein, “linker nucleoside” means a nucleoside that directly or indirectly conjugates an oligonucleotide to the conjugate moiety. Linker nucleosides are located within the conjugate linker of the oligomeric compound. Linker nucleosides are not considered part of the oligonucleotide moiety of the oligomeric compound, even if they are contiguous with the oligonucleotide.
[0046] As used herein, “non-bicyclic modified sugar moiety” means a modified sugar moiety that includes modifications such as substituents that do not form a bridge between the two sugar atoms to form a second ring.
[0047] As used herein, “mismatch” or “non-complementary” means a nucleic acid base of the first oligonucleotide that is not complementary to the second oligonucleotide or the corresponding nucleic acid base of the target nucleic acid when the first and second oligonucleotides are aligned.
[0048] As used herein, “motif” means the pattern of unmodified and / or modified sugar moieties, nucleic acid bases, and / or nucleoside bonds in an oligonucleotide.
[0049] As used herein, “nucleic acid base” means an unmodified or modified nucleic acid base. As used herein, “unmodified nucleic acid base” is adenine (A), thymine (T), cytosine (C), uracil (U), or guanine (G). As used herein, “modified nucleic acid base” is an atomic group other than unmodified A, T, C, U, or G that can pair with at least one unmodified nucleic acid base. “5-methylcytosine” is a modified nucleic acid base. A universal base is a nucleic acid base that can pair with any one of the five unmodified nucleic acid bases. As used herein, “nucleic acid base sequence” means a sequence of nucleic acid bases in a target nucleic acid or oligonucleotide, independent of any sugar or nucleoside bond modifications.
[0050] As used herein, “nucleoside” means a compound or fragment of a compound comprising a nucleic acid base and a sugar moiety. The nucleic acid base and sugar moiety are, independently, either unmodified or modified. As used herein, “modified nucleoside” means a nucleoside comprising a modified nucleic acid base and / or a modified sugar moiety. Modified nucleosides include debasic nucleosides lacking a nucleic acid base. “Bound nucleosides” means nucleosides linked in a contiguous sequence (i.e., no further nucleosides between bound nucleosides).
[0051] As used herein, “oligomer compound” means an oligonucleotide and, optionally, one or more additional features such as a conjugate group or terminal group. An oligomer compound may or may not be paired with a second oligomer compound complementary to a first oligomer compound. A “single-stranded oligomer compound” is an unpaired oligomer compound. The term “oligomer double-stranded” means a double-stranded structure formed by two oligomer compounds having complementary nucleic acid base sequences. Each oligomer compound in an oligomer double-stranded structure may be referred to as a “double-stranded oligomer compound.”
[0052] As used herein, “oligonucleotide” means a chain of linked nucleosides connected via nucleoside-nucleoside bonds, where each nucleoside and nucleoside-nucleoside bond may be modified or unmodified. Unless otherwise indicated, an oligonucleotide consists of 8 to 50 linked nucleosides. As used herein, “modified oligonucleotide” means an oligonucleotide in which at least one nucleoside or nucleoside-nucleoside bond is modified. As used herein, “unmodified oligonucleotide” means an oligonucleotide that does not contain any nucleoside modifications or nucleoside-nucleoside modifications.
[0053] As used herein, “organ injury” or “peripheral organ injury” refers to injury to major organs nourished by the circulatory system, such as the heart (e.g., myocardial hypertrophy, cardiac dysfunction, and / or heart failure), the kidneys (e.g., albuminurea, proteinurea, renal dysfunction, and / or renal failure), the eyes (e.g., hypertensive retinopathy), and the brain (e.g., stroke). Organs can be injured by hypertension in animals. In certain embodiments, cardiac injury is fibrosis, cardiac cell hypertrophy, and / or myometriosis resulting in cardiac hypertrophy.
[0054] As used herein, “pharmaceutically acceptable carrier or diluent” means any substance suitable for use in administering to a subject. Certain such carriers enable the formulation of a pharmaceutical composition into, for example, pills, tablets, sugar-coated tablets, capsules, liquids, gels, syrups, slurries, suspensions, and lozenges for oral administration by a subject. In certain embodiments, the pharmaceutically acceptable carrier or diluent is sterile water, sterile saline, sterile buffer, or sterile artificial cerebrospinal fluid.
[0055] As used herein, “pharmaceutically acceptable salt” means a physiologically and pharmaceutically acceptable salt of a compound. A pharmaceutically acceptable salt retains the desired biological activity of the parent compound and does not impart any undesirable toxicological effects to the parent compound.
[0056] As used herein, “pharmaceutical composition” means a mixture of substances suitable for administration to a subject. For example, a pharmaceutical composition may include an oligomeric compound and a sterile aqueous solution. In certain embodiments, the pharmaceutical composition exhibits activity in a free uptake assay in a particular cell line.
[0057] As used herein, “prodrug” means a therapeutic agent that is an ex vivo form that is converted into a different form within a subject or its cells. Generally, the conversion of a prodrug within a subject is facilitated by the action of enzymes (e.g., endogenous enzymes or viral enzymes) or chemicals present in the cell or tissue, and / or by physiological conditions.
[0058] As used herein, “reduce amount or activity” means a reduction or blockage of transcriptional expression or activity in an untreated or control sample, and does not necessarily mean the complete elimination of transcriptional expression or activity.
[0059] As used herein, the terms "renin-angiotensin-aldosterone system," "renin-angiotensin-aldosterone pathway," "RAAS pathway," or "RAAS" refer to a multicomponent enzyme pathway in which a precursor component (angiotensinogen) is converted to downstream components such as angiotensin I and angiotensin II by various enzymes, including renin and the enzyme angiotensin-converting enzyme (ACE). Angiotensin I stimulates the secretion of the steroid aldosterone in the pathway. The RAAS pathway regulates blood pressure and fluid balance.
[0060] As used herein, “renin-angiotensin system,” “RAS,” or “RAS pathway” refers to a part of the RAAS pathway. Various components of this pathway are targeted by agonists or antagonists to block the production of these components. For example, renin inhibitors, ACE inhibitors, and angiotensin receptor blockers (ARBs) have been developed to inhibit or block the RAS pathway. However, commercially available therapies targeting various RAS pathway components have not been effective in completely inhibiting or blocking the RAS pathway due to various mechanisms or adverse effects (Nobakht et al., Nat Rev Nephrol, 2011, 7:356-359).
[0061] As used herein, “RAAS-related disease, disorder, and / or condition” or “RAAS pathway-related disease, disorder, and / or condition” refers to any disease, disorder, or condition in animals associated with the RAAS. Examples of RAAS-related diseases, disorders, and / or conditions include shortened life expectancy, hypertension (e.g., non-resistant hypertension, resistant hypertension), kidney disease (e.g., chronic kidney disease, polycystic kidney disease), stroke, heart disease (e.g., myocardial infarction, heart failure, valvular heart disease), aneurysms of blood vessels (e.g., aortic aneurysm), peripheral artery disease, organ injury (e.g., cardiac injury or hypertrophy), histofibrosis, and other cardiovascular diseases, disorders, and / or conditions, or their symptoms. In certain embodiments, RAAS-related diseases, disorders, and / or conditions do not include hypertension.
[0062] As used herein, “resistant hypertension” or “RHTN” is defined as either a) blood pressure exceeding the therapeutic objective (typically ≥130 / 80 mmHg) despite the simultaneous use of three or more antihypertensive agents from different drug classes administered at maximum tolerated doses, or b) blood pressure controlled to below the therapeutic objective only after administration of at least four antihypertensive agents from different classes to achieve control.
[0063] As used herein, "RNA" means RNA transcripts, and unless otherwise specified, includes pre-mRNA and mature mRNA.
[0064] As used herein, “RNAi compound” means an antisense compound that acts to modulate a target nucleic acid and / or the protein encoded by the target nucleic acid, at least partially via RISC or Ago2. RNAi compounds include, but are not limited to, double-stranded siRNA, single-stranded RNA (ssRNA), and microRNA, including microRNA mimetic compounds. In certain embodiments, the RNAi compound modulates the quantity, activity, and / or splicing of the target nucleic acid. The term RNAi compound excludes antisense compounds that act via RNaseH.
[0065] As used herein with respect to oligonucleotides, “self-complementary” means an oligonucleotide that hybridizes at least partially with itself.
[0066] As used herein, “standard in vitro assay” means the assay described in the examples and reasonable variations thereof.
[0067] As used herein, “standard in vivo assay” means the assay described in the examples and reasonable variations thereof.
[0068] As used herein, “stereorandom chiral center” in the context of a group of molecules of the same molecular formula means a chiral center having a random stereochemical configuration. For example, in a group of molecules containing stereorandom chiral centers, the number of molecules having the (S) configuration of the stereorandom chiral center may be the same as, but not necessarily the same as, the number of molecules having the (R) configuration of the stereorandom chiral center. The stereochemical configuration of a chiral center is considered random if it is the result of a synthetic method not designed to control the stereochemical configuration. In certain embodiments, a stereorandom chiral center is a stereorandom phosphorothioate nucleoside bond.
[0069] As used herein, “subject” means human or non-human animal.
[0070] As used herein, “sugar moiety” means an unmodified sugar moiety or a modified sugar moiety. As used herein, “unmodified sugar moiety” means a 2'-OH(H)β-D-ribosyl moiety found in RNA ("unmodified RNA sugar moiety") or a 2'-H(H)β-D-deoxyribosyl sugar moiety found in DNA ("unmodified DNA sugar moiety"). An unmodified sugar moiety has one hydrogen atom at each of the 1', 3', and 4' positions, one oxygen atom at the 3' position, and two hydrogen atoms at the 5' position. As used herein, “modified sugar moiety” or “modified sugar” means a modified furanosyl sugar moiety or sugar surrogate.
[0071] As used herein, “sugar surrogate” means a modified sugar moiety having a nucleoside base other than a furanosyl moiety that can be bound to another group in the oligonucleotide, such as an internucleoside bond, a conjugate group, or a terminal group. Modified nucleosides containing sugar surrogates can be conjugated at one or more positions within an oligonucleotide, and such oligonucleotides can hybridize to complementary oligomeric compounds or target nucleic acids.
[0072] As used herein, “symptom” or “characteristic” means any physical feature or test result indicating the presence or degree of a disease or disorder. In certain embodiments, symptoms are evident to the subject or a medical professional examining or testing the subject. In certain embodiments, characteristics are evident by invasive diagnostic tests, including but not limited to post-mortem examinations.
[0073] As used herein, “target nucleic acid” and “target RNA” mean the nucleic acid to which an antisense compound is designed to act.
[0074] As used herein, “target region” means the portion of a target nucleic acid with which an oligomeric compound is designed to hybridize.
[0075] As used herein, “end group” means a chemical group or atomic group covalently bonded to the end of an oligonucleotide.
[0076] As used herein, “therapeutic dose” means the amount of a medicinal agent that provides a therapeutic effect to a subject. For example, a therapeutic dose improves the symptoms of a disease.
[0077] Specific Embodiments This disclosure provides the following non-limiting numbered embodiments.
[0078] Embodiment 1: An oligomeric compound comprising a modified oligonucleotide having a nucleic acid base sequence consisting of 14 to 30 bound nucleosides and containing at least 14, at least 15, or 16 consecutive nucleic acid bases from any of the nucleic acid base sequences of SEQ ID NOs. 12 to 15, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified nucleoside bond.
[0079] Embodiment 2: Consists of 14 to 30 bound nucleosides, The equal-length portion of nucleic acid bases 2046-2061 in Sequence ID No. 1, The equal-length portion of nucleic acid bases 2271-2286 in sequence number 1, The equal-length portion of nucleic acid bases 2272-2287 in sequence number 1, An oligomeric compound comprising a modified oligonucleotide having a nucleic acid base sequence comprising at least 14, at least 15, or at least 16 consecutive nucleic acid bases complementary to the oligonucleotide, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified nucleoside bond.
[0080] Embodiment 3: An oligomeric compound comprising a modified oligonucleotide having a nucleic acid base sequence comprising 16 bonded nucleosides and including the nucleic acid base sequence of SEQ ID NO: 12, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified nucleoside bond.
[0081] Embodiment 4: An oligomeric compound comprising a modified oligonucleotide having a nucleic acid base sequence comprising 16 bonded nucleosides and including the nucleic acid base sequence of SEQ ID NO: 13, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified nucleoside bond.
[0082] Embodiment 5: An oligomeric compound comprising a modified oligonucleotide having a nucleic acid base sequence comprising 16 bonded nucleosides and including the nucleic acid base sequence of SEQ ID NO: 14, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified nucleoside bond.
[0083] Embodiment 6: An oligomeric compound comprising a modified oligonucleotide having a nucleic acid base sequence comprising 16 bonded nucleosides and including the nucleic acid base sequence of SEQ ID NO: 15, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified nucleoside bond.
[0084] Embodiment 7: An oligomer compound according to any one of Embodiments 1 to 6, wherein the modified oligonucleotide has a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% complementary to the nucleic acid sequence of any SEQ ID NO: 1 or SEQ ID NO: 2 when measured across the entire nucleic acid sequence of the modified oligonucleotide.
[0085] Embodiment 8: Any of the oligomeric compounds according to Embodiments 1 to 7, wherein the modified oligonucleotide comprises at least one bicyclic sugar moiety.
[0086] Embodiment 9: The oligomer compound according to Embodiment 8, wherein the bicyclic sugar moiety has a 4'-2' crosslink, and the 4'-2' crosslink is selected from -CH2-O- and -CH(CH3)-O-.
[0087] Embodiment 10: The oligomer compound according to any one of Embodiments 1 to 9, wherein the modified oligonucleotide comprises at least one non-bicyclic modified sugar moiety.
[0088] Embodiment 11: The oligomer compound according to Embodiment 10, wherein the non-bicyclic modified sugar moiety is a 2'-MOE sugar moiety or a 2'-OMe sugar moiety.
[0089] Embodiment 12: The oligomeric compound according to any one of Embodiments 1 to 11, wherein the modified oligonucleotide comprises at least one sugar surrogate.
[0090] Embodiment 13: The oligomer compound according to Embodiment 12, wherein the sugar surrogate is one of morpholino, modified morpholino, PNA, THP, and F-HNA.
[0091] Embodiment 14: The oligomeric compound according to any one of Embodiments 1 to 13, wherein the modified oligonucleotide is a gapmer.
[0092] Embodiment 15: Modified oligonucleotides A 5' region consisting of 1 to 6 bonded 5' region nucleosides, The central region consists of 6 to 10 bound central region nucleosides, A 3' region consisting of 1 to 6 bonded 3' region nucleosides, It contains a sugar motif, The oligomer compound according to Embodiment 14, wherein each of the 5' region nucleosides and each of the 3' region nucleosides contains a modified sugar moiety, and at least six of the central region nucleosides contain a 2'-β-D-deoxyribosyl sugar moiety.
[0093] Embodiment 16: Modified oligonucleotides A 5' region consisting of 1 to 6 bonded 5' region nucleosides, The central region consists of 6 to 10 bound central region nucleosides, A 3' region consisting of 1 to 6 bonded 3' region nucleosides, It contains a sugar motif, The oligomer compound according to Embodiment 14, wherein each of the 5' region nucleosides and each of the 3' region nucleosides contains a modified sugar moiety, and each of the central region nucleosides contains a 2'-deoxyribosyl sugar moiety.
[0094] Embodiment 17: Modified oligonucleotides A 5' region consisting of three bonded 5' region nucleosides, A central region consisting of 10 bound central region nucleosides, A 3' region consisting of three bonded 3' region nucleosides, It contains a sugar motif, The oligomer compound according to Embodiment 14, wherein each of the 5' region nucleosides and each of the 3' region nucleosides contains a 2'-MOE sugar moiety or a cEt-modified sugar moiety, and each of the central region nucleosides contains a 2'-β-D-deoxyribosyl sugar moiety.
[0095] Embodiment 18: Modified oligonucleotides A 5' region consisting of three bonded 5' region nucleosides, A central region consisting of 10 bound central region nucleosides, A 3' region consisting of three bonded 3' region nucleosides, It contains a sugar motif, The oligomer compound according to Embodiment 14, wherein each of the 5' region nucleosides and each of the 3' region nucleosides contains a 2'-MOE modified sugar moiety or a cEt modified sugar moiety, and at least six of the central region nucleosides contain a 2'-β-D-deoxyribosyl sugar moiety.
[0096] Embodiment 19: An oligomer compound according to any one of Embodiments 1 to 18, wherein the modified oligonucleotide has a sugar motif (5' to 3') selected from eekddddddddddkke, ekkddddddddddkke, kkkdydddddddddkkk, kkkddydddddddddkkk, kkkdddyddddddddkkk, kkkddddddddddddkkk, or eeeeeddddddddddeeeee, where "e" represents the 2'-MOE sugar moiety, "k" represents the cEt sugar moiety, "d" represents the 2'-β-D-deoxyribosyl sugar moiety, and "y" represents the 2'-OMe sugar moiety.
[0097] Embodiment 20: The oligomer compound according to any one of Embodiments 1 to 19, wherein the modified oligonucleotide comprises at least one modified internucleoside bond.
[0098] Embodiment 21: The oligomer compound according to Embodiment 20, wherein each nucleoside bond in the modified oligonucleotide is a modified nucleoside bond.
[0099] Embodiment 22: The oligomer compound according to Embodiment 20 or Embodiment 21, wherein at least one nucleoside bond is a phosphorothioate nucleoside bond.
[0100] Embodiment 23: The oligomer compound according to any one of Embodiments 20 and 22, wherein the modified oligonucleotide comprises at least one phosphodiester nucleoside interbonding linkage.
[0101] Embodiment 24: The oligomer compound according to any one of Embodiments 20, 22, and 23, wherein each nucleoside bond is either a phosphodiester nucleoside bond or a phosphorothioate nucleoside bond.
[0102] Embodiment 25: The oligomer compound according to Embodiment 21, wherein each nucleoside bond is a phosphorothioate nucleoside bond.
[0103] Embodiment 26: The modified oligonucleotide has a nucleoside-to-nucleoside binding motif of soossssssssssos, in the formula, The oligomer compound according to any one of Embodiments 1 to 20 or 22 to 24, wherein s is a phosphorothioate nucleoside bond and o is a phosphodiester nucleoside bond.
[0104] Embodiment 27: The oligomer compound according to any one of Embodiments 1 to 26, wherein the modified oligonucleotide comprises at least one modified nucleic acid base.
[0105] Embodiment 28: The oligomer compound according to Embodiment 27, wherein the modified nucleic acid base is 5-methylcytosine.
[0106] Embodiment 29: The oligomer compound according to any one of Embodiments 1 to 28, wherein the modified oligonucleotide consists of 12-30, 12-22, 12-20, 14-18, 14-20, 15-17, 15-25, or 16-20 bonded nucleosides.
[0107] Embodiment 30: The oligomeric compound according to any one of Embodiments 1 to 28, wherein the modified oligonucleotide consists of 16 bound nucleosides.
[0108] Embodiment 31: An oligomer compound according to any one of Embodiments 1 to 30, comprising a conjugate group.
[0109] Embodiment 32: The oligomer compound according to Embodiment 31, wherein the conjugate group comprises a GalNAc cluster containing 1 to 3 GalNAc ligands.
[0110] Embodiment 33: The oligomer compound according to any one of Embodiments 31 and 32, wherein the conjugate group comprises a conjugate linker consisting of a single bond.
[0111] Embodiment 34: The oligomer compound according to any one of Embodiments 31 to 33, wherein the conjugate group includes a cleavable linker.
[0112] Embodiment 35: The oligomer compound according to any one of Embodiments 31 to 34, wherein the conjugate group comprises a conjugate linker containing 1 to 3 linker nucleosides.
[0113] Embodiment 36: The oligomer compound according to any one of Embodiments 31 to 35, wherein the conjugate group is bonded to the modified oligonucleotide at the 5' end of the modified oligonucleotide.
[0114] Embodiment 37: The oligomer compound according to any one of Embodiments 31 to 35, wherein the conjugate group is bonded to the modified oligonucleotide at the 3' end of the modified oligonucleotide.
[0115] Embodiment 38: The oligomer compound according to any one of Embodiments 1 to 37, wherein the oligomer compound is a single-chain oligomer compound.
[0116] Embodiment 39: An oligomeric compound according to any one of Embodiments 1 to 30 or 38, comprising a modified oligonucleotide.
[0117] Embodiment 40: An oligomeric double chain comprising the oligomeric compound described in any of Embodiments 1 to 37.
[0118] Embodiment 41: An antisense compound comprising, or consisting thereof, an oligomeric compound described in any of Embodiments 1 to 39 or an oligomeric double chain described in Embodiment 40.
[0119] Embodiment 42: A pharmaceutical composition comprising an oligomeric compound according to any of Embodiments 1 to 39 or an oligomeric double chain according to Embodiment 40, and a pharmaceutically acceptable carrier or diluent.
[0120] Embodiment 43: The following chemical structure:
[0121] [ka]
[0122] A compound, or a salt thereof, according to (Sequence No. 12).
[0123] Embodiment 44: The following chemical structure:
[0124] [ka]
[0125] A compound according to (Sequence ID 12).
[0126] Embodiment 45: The following chemical structure:
[0127] [ka]
[0128] A compound, or a salt thereof, according to (Sequence ID 13).
[0129] Embodiment 46: The following chemical structure:
[0130] [ka]
[0131] A compound according to (Sequence ID 13).
[0132] Embodiment 47: The following chemical structure:
[0133] [ka]
[0134] A compound, or a salt thereof, according to (Sequence ID 14).
[0135] Embodiment 48: The following chemical structure:
[0136] [ka]
[0137] A compound according to (Sequence ID 14).
[0138] Embodiment 49: The following chemical structure:
[0139] [ka]
[0140] A compound, or a salt thereof, according to (Sequence ID 15).
[0141] Embodiment 50: The following chemical structure:
[0142] [ka]
[0143] A compound according to (SEQ ID NO: 15).
[0144] Embodiment 51: A modified oligonucleotide according to any of Embodiments 43, 45, 47, and 49, which is a sodium salt or potassium salt of the chemical structure.
[0145] Embodiment 52: A pharmaceutical composition comprising the modified oligonucleotide according to any one of Embodiments 43 to 51 and a pharmaceutically acceptable carrier or diluent.
[0146] Embodiment 53: The following chemical notation: m C es G eo m C ko T ds G ds A ds T ds T ds T ds G ds T ds m C ds m C ds G ko G ks G e (SEQ ID NO: 12) A compound comprising a modified oligonucleotide according to, wherein, A is an adenine nucleobase, m C is a 5-methylcytosine nucleobase, G is a guanine nucleobase, T is a thymine nucleobase, e is a 2'-β-D-MOE sugar moiety, k is a cEt sugar moiety, d is a 2'-β-D-deoxyribosyl sugar moiety, s is a phosphorothioate nucleoside internucleoside linkage, o is a phosphodiester nucleoside internucleoside linkage, a compound.
[0147] Embodiment 54: The following chemical notation: T es m C ko G ko G ds T ds T ds G ds G ds A ds A ds T ds T ds m Cds T ko T ks T e A compound comprising a modified oligonucleotide according to (SEQ ID NO: 13), wherein, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, e is the 2'-β-D-MOE sugar moiety, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, s is a phosphorothioate nucleoside bond, A compound in which o is a phosphodiester nucleoside bond.
[0148] Embodiment 55: Chemical notation as follows: G ks T ks m C ks G ds G ys T ds T ds G ds G ds A ds A ds T ds T ds m C ks T ks T k A compound comprising a modified oligonucleotide according to (SEQ ID NO: 15), wherein the formula, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, y is the 2'-OMe ribose sugar moiety, A compound in which s is a phosphorothioate nucleoside bond.
[0149] Embodiment 56: Chemical notation as follows: T ks m C ko G ko G ds U ys T ds G ds G ds A ds A ds T ds T ds m C ds T ko T ks T k A compound comprising a modified oligonucleotide according to (SEQ ID NO: 14), wherein the formula, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, U is the uracil nucleic acid base, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, y is the 2'-OMe ribose sugar moiety, s is a phosphorothioate nucleoside bond, A compound in which o is a phosphodiester nucleoside bond.
[0150] Embodiment 57: A compound according to any one of Embodiments 53 to 56, comprising a modified oligonucleotide covalently bonded to a conjugate group.
[0151] Embodiment 58: A pharmaceutical composition according to any one of Embodiments 53 to 56, and a pharmaceutically acceptable diluent or carrier.
[0152] Embodiment 59: A chirally enriched population of the modified oligonucleotides according to any one of Embodiments 53 to 56, wherein the population is enriched for modified oligonucleotides comprising at least one specific phosphorothioate internucleoside linkage having a specific stereochemical configuration, the chirally enriched population.
[0153] Embodiment 60: The chirally enriched population according to Embodiment 59, wherein the population is enriched for modified oligonucleotides comprising at least one specific phosphorothioate internucleoside linkage having an (Sp) configuration.
[0154] Embodiment 61: The chirally enriched population according to Embodiment 59, wherein the population is enriched for modified oligonucleotides comprising at least one specific phosphorothioate internucleoside linkage having an (Rp) configuration.
[0155] Embodiment 62: The chirally enriched population according to Embodiment 59, wherein the population is enriched for modified oligonucleotides having a specifically and independently selected stereochemical configuration at each phosphorothioate internucleoside linkage.
[0156] Embodiment 63: The chirally enriched population according to Embodiment 59, wherein the population is enriched for modified oligonucleotides having an (Sp) configuration at each phosphorothioate internucleoside linkage or for modified oligonucleotides having an (Rp) configuration at each phosphorothioate internucleoside linkage.
[0157] Embodiment 64: The chirally enriched population according to Embodiment 59, wherein the population is enriched for modified oligonucleotides having an (Rp) configuration at one specific phosphorothioate internucleoside linkage and an (Sp) configuration at each of the remaining phosphorothioate internucleoside linkages.
[0158] Embodiment 65: The chiralally enriched population according to Embodiment 59, wherein the population is enriched with respect to modified oligonucleotides having at least three consecutive phosphorothioate nucleoside bonds in Sp configuration, Sp configuration, and Rp configuration in the 5' to 3' direction.
[0159] Embodiment 66: A group of modified oligonucleotides according to any of Embodiments 59 to 65, wherein all of the phosphorothioate nucleoside bonds of the modified oligonucleotides are stereorandom.
[0160] Embodiment 67: A method comprising administering a pharmaceutical composition described in any prior embodiment to an individual.
[0161] Embodiment 68: A method for treating a disease related to the RAAS pathway, comprising administering a therapeutically effective amount of the pharmaceutical composition described in any of the preceding embodiments to an individual having or at risk of having a disease related to the RAAS pathway, thereby treating the disease related to the RAAS pathway.
[0162] Embodiment 69: The method according to Embodiment 68, wherein the disease is a cardiovascular disease.
[0163] Embodiment 70: The method according to any one of Embodiments 68 and 69, wherein the disease is selected from hypertension, resistant hypertension, Marfan syndrome, heart failure, kidney disease, obesity, metabolic syndrome, NASH, and NAFLD.
[0164] Embodiment 71: The method according to any one of Embodiments 68 to 70, wherein at least one symptom or characteristic of the disease is improved.
[0165] Embodiment 72: The method according to Embodiment 71, wherein the symptom or characteristic is any of the following: hypertension, hypertensive emergency (i.e., malignant hypertension), stroke, pre-eclampsia, vascular aneurysm, abdominal aneurysm, peripheral artery disease, organ injury, or pulmonary hypertension.
[0166] Embodiment 73: The method according to any one of Embodiments 67 to 72, wherein the pharmaceutical composition is administered systemically.
[0167] Embodiment 74: The method according to any one of Embodiments 73, wherein the pharmaceutical composition is administered either subcutaneously or intramuscularly.
[0168] Embodiment 75: Use of an oligomeric compound according to any of Embodiments 1 to 37 or an oligomeric double-chain according to Embodiment 40 to reduce intracellular AGT expression.
[0169] Embodiment 76: The use described in Embodiment 75, wherein the level of AGT RNA is reduced.
[0170] Embodiment 77: The use described in Embodiment 75, wherein the level of AGT protein is reduced.
[0171] Embodiment 78.14 An oligomeric compound comprising a modified oligonucleotide having a nucleic acid base sequence comprising 30 bonded nucleosides and at least 14, at least 15, or at least 16 consecutive nucleic acid bases from any of the nucleic acid base sequences of SEQ ID NOs. 12 to 15, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified nucleoside bond.
[0172] Embodiment 79.14 consists of 30 bound nucleosides, a. The equal-length portion of nucleic acid bases 2046-2061 of Sequence ID No. 1, b. The equal-length portion of nucleic acid bases 2271-2286 in Sequence ID No. 1, c. The equal-length portion of nucleic acid bases 2272-2287 in Sequence ID No. 1, An oligomeric compound comprising a modified oligonucleotide having a nucleobase sequence comprising at least 14, at least 15, or at least 16 consecutive nucleobases complementary to , wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
[0173] Embodiment 80. An oligomeric compound comprising a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 12, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
[0174] Embodiment 81. An oligomeric compound comprising a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 13, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
[0175] Embodiment 82. An oligomeric compound comprising a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 14, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
[0176] Embodiment 83. An oligomeric compound comprising a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 15, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
[0177] Embodiment 84. An oligomer compound according to any of Embodiments 78 to 83, wherein the modified oligonucleotide has a nucleic acid base sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% complementary to the nucleic acid base sequence of any SEQ ID NO: 1 or SEQ ID NO: 2 when measured across the entire nucleic acid base sequence of the modified oligonucleotide.
[0178] Embodiment 85. Any of the oligomeric compounds according to Embodiments 78 to 84, wherein the modified oligonucleotide comprises at least one bicyclic sugar moiety.
[0179] Embodiment 86. The oligomer compound according to Embodiment 85, wherein the bicyclic sugar moiety has a 4'-2' crosslink, and the 4'-2' crosslink is selected from -CH2-O- and -CH(CH3)-O-.
[0180] Embodiment 87. An oligomer compound according to any one of Embodiments 78 to 86, wherein the modified oligonucleotide comprises at least one non-bicyclic modified sugar moiety.
[0181] Embodiment 88. The oligomer compound according to Embodiment 87, wherein the non-bicyclic modified sugar moiety is a 2'-MOE sugar moiety or a 2'-OMe sugar moiety.
[0182] Embodiment 89. An oligomeric compound according to any one of Embodiments 78 to 88, wherein the modified oligonucleotide comprises at least one sugar surrogate.
[0183] Embodiment 90. The oligomer compound according to Embodiment 89, wherein the sugar surrogate is one of morpholino, modified morpholino, PNA, THP, and F-HNA.
[0184] Embodiment 91. An oligomer compound according to any one of Embodiments 78 to 90, wherein the modified oligonucleotide is a gapmer.
[0185] Embodiment 92. Modified oligonucleotides A 5' region consisting of 1 to 6 bonded 5' region nucleosides, The central region consists of 6 to 10 bound central region nucleosides, A 3' region consisting of 1 to 6 bonded 3' region nucleosides, It contains a sugar motif, The oligomer compound according to any one of Embodiments 78 to 91, wherein each of the 5' region nucleosides and each of the 3' region nucleosides contains a modified sugar moiety, and at least six of the central region nucleosides contain a 2'-β-D-deoxyribosyl sugar moiety.
[0186] Embodiment 93. Modified oligonucleotides A 5' region consisting of 1 to 6 bonded 5' region nucleosides, The central region consists of 6 to 10 bound central region nucleosides, A 3' region consisting of 1 to 6 bonded 3' region nucleosides, It contains a sugar motif, The oligomer compound according to any one of Embodiments 78 to 91, wherein each of the 5' region nucleosides and each of the 3' region nucleosides contains a modified sugar moiety, and each of the central region nucleosides contains a 2'-deoxyribosyl sugar moiety.
[0187] Embodiment 94. Modified oligonucleotides A 5' region consisting of three bonded 5' region nucleosides, A central region consisting of 10 bound central region nucleosides, A 3' region consisting of three bonded 3' region nucleosides, It contains a sugar motif, The oligomer compound according to any one of Embodiments 78 to 91, wherein each of the 5' region nucleosides and each of the 3' region nucleosides contains a 2'-MOE sugar moiety or a cEt sugar moiety, and each of the central region nucleosides contains a 2'-β-D-deoxyribosyl sugar moiety.
[0188] Embodiment 95. Modified oligonucleotides A 5' region consisting of three bonded 5' region nucleosides, A central region consisting of 10 bound central region nucleosides, A 3' region consisting of 43 bonded 3' region nucleosides, It contains a sugar motif, The oligomer compound according to any one of Embodiments 78 to 91, wherein each of the 5' region nucleosides and each of the 3' region nucleosides contains a 2'-MOE sugar moiety or a cEt sugar moiety, and at least six of the central region nucleosides contain a 2'-β-D-deoxyribosyl sugar moiety.
[0189] Embodiment 96. An oligomer compound according to any one of Embodiments 78 to 95, wherein the modified oligonucleotide has a sugar motif (5' to 3') selected from eekddddddddddkke, ekkddddddddddkke, kkkdyddddddddkkk, kkkddydddddddddkkk, kkkdddyddddddddkkk, kkkddddddddddddkkk, or eeeeeddddddddddeeeee, where "e" represents the 2'-MOE sugar moiety, "k" represents the cEt sugar moiety, "d" represents the 2'-β-D-deoxyribosyl sugar moiety, and "y" represents the 2'-OMe sugar moiety.
[0190] Embodiment 97. An oligomer compound according to any one of Embodiments 78 to 96, wherein the modified oligonucleotide comprises at least one modified internucleoside bond.
[0191] Embodiment 98. The oligomer compound according to Embodiment 97, wherein each nucleoside bond in the modified oligonucleotide is a modified nucleoside bond.
[0192] Embodiment 99. The oligomer compound according to Embodiment 97 or Embodiment 98, wherein at least one nucleoside bond is a phosphorothioate nucleoside bond.
[0193] Embodiment 100. The oligomer compound according to either Embodiment 97 or Embodiment 99, wherein the modified oligonucleotide comprises at least one phosphodiester nucleoside interbonding linkage.
[0194] Embodiment 101. The oligomer compound according to any one of Embodiments 97, 99, and 100, wherein each nucleoside bond is either a phosphodiester nucleoside bond or a phosphorothioate nucleoside bond.
[0195] Embodiment 102. The oligomer compound according to Embodiment 98, wherein each nucleoside bond is a phosphorothioate nucleoside bond.
[0196] Embodiment 103. The modified oligonucleotide has a nucleoside-to-nucleoside binding motif of soossssssssssos, in the formula, s is a phosphorothioate nucleoside bond, o is a phosphodiester nucleoside bond. The oligomer compound according to any one of embodiments 78-97 or 99-101.
[0197] Embodiment 104. An oligomer compound according to any one of Embodiments 78 to 103, wherein the modified oligonucleotide comprises at least one modified nucleic acid base.
[0198] Embodiment 105. The oligomer compound according to Embodiment 104, wherein the modified nucleic acid base is 5-methylcytosine.
[0199] Embodiment 106. An oligomer compound according to any of Embodiments 78 to 105, wherein the modified oligonucleotide consists of 14-30, 14-22, 14-20, 14-18, 14-20, 15-17, 15-25, or 16-20 bonded nucleosides.
[0200] Embodiment 107. An oligomer compound according to any one of Embodiments 78 to 106, wherein the modified oligonucleotide consists of 16 linked nucleosides.
[0201] Embodiment 108. An oligomer compound according to any one of Embodiments 78 to 107, comprising a conjugate group.
[0202] Embodiment 109. The oligomer compound according to Embodiment 108, wherein the conjugate group comprises a GalNAc cluster containing 1 to 3 GalNAc ligands.
[0203] Embodiment 110. An oligomer compound according to any one of Embodiments 108 and 109, wherein the conjugate group comprises a conjugate linker consisting of a single bond.
[0204] Embodiment 111. An oligomer compound according to any one of Embodiments 108 to 110, wherein the conjugate group includes a cleavable linker.
[0205] Embodiment 112. An oligomer compound according to any one of Embodiments 108 to 111, wherein the conjugate group comprises a conjugate linker containing 1 to 3 linker nucleosides.
[0206] Embodiment 113. The oligomer compound according to any one of Embodiments 108 to 112, wherein the conjugate group is the 5'-nucleoside of the modified oligonucleotide, and is bound to the modified oligonucleotide.
[0207] Embodiment 114. The oligomer compound according to any one of Embodiments 108 to 113, wherein the conjugate group is the 3'-nucleoside of the modified oligonucleotide, and is bound to the modified oligonucleotide.
[0208] Embodiment 115. An oligomer compound according to any one of Embodiments 78 to 114, wherein the oligomer compound is a single-chain oligomer compound.
[0209] Embodiment 116. An oligomeric compound according to any one of Embodiments 78 to 107 or 115, comprising a modified oligonucleotide.
[0210] Embodiment 117. The following chemical structure:
[0211] [ka]
[0212] An oligomeric compound, or a salt thereof, according to (Sequence No. 12).
[0213] Embodiment 118. The following chemical structure:
[0214] [ka]
[0215] An oligomeric compound according to (Sequence No. 12).
[0216] Embodiment 119. The following chemical structure:
[0217] [ka]
[0218] An oligomeric compound, or a salt thereof, according to (Sequence ID 13).
[0219] Embodiment 120. The following chemical structure:
[0220] [ka]
[0221] An oligomeric compound according to (SEQ ID NO: 13).
[0222] Embodiment 121. The following chemical structure:
[0223] [ka]
[0224] An oligomeric compound, or a salt thereof, according to (Sequence ID 14).
[0225] Embodiment 122. The following chemical structure:
[0226] [ka]
[0227] An oligomeric compound according to (SEQ ID NO: 14).
[0228] Embodiment 123. The following chemical structure:
[0229] [ka]
[0230] An oligomeric compound, or a salt thereof, according to (Sequence ID 15).
[0231] Embodiment 124. The following chemical structure:
[0232] [ka]
[0233] An oligomeric compound according to (SEQ ID NO: 15).
[0234] Embodiment 125. An oligomer compound according to any one of Embodiments 117, 119, 121, or 123, which is a sodium salt or a potassium salt.
[0235] Embodiment 126. Chemical notation as follows: m C es G eo m C ko Tds G ds A ds T ds T ds T ds G ds T ds m C ds m C ds G ko G ks G e (SEQ ID NO: 12)-conforming modified oligonucleotide, an oligomeric compound, wherein A is an adenine nucleobase, m C is a 5-methylcytosine nucleobase, G is a guanine nucleobase, T is a thymine nucleobase, e is a 2'-β-D-MOE sugar moiety, k is a cEt sugar moiety, d is a 2'-β-D-deoxyribosyl sugar moiety, s is a phosphorothioate internucleoside linkage, o is a phosphodiester internucleoside linkage, an oligomeric compound.
[0236] Embodiment 127. The following chemical notation: T es m C ko G ko G ds T ds T ds G ds G ds A ds A ds T ds T ds m C ds T ko T ks T e (SEQ ID NO: 13)-conforming modified oligonucleotide, an oligomeric compound, wherein A is an adenine nucleobase, m C is a 5-methylcytosine nucleobase, G is a guanine nucleic acid base, T is a thymine nucleic acid base, e is the 2'-β-D-MOE sugar moiety, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, s is a phosphorothioate nucleoside bond, An oligomeric compound in which o is a phosphodiester nucleoside bond.
[0237] Embodiment 128. Chemical notation below: G ks T ks m C ks G ds G ys T ds T ds G ds G ds A ds A ds T ds T ds m C ks T ks T k An oligomeric compound comprising a modified oligonucleotide according to (SEQ ID NO: 15), wherein, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, y is the 2'-OMe ribose sugar moiety, An oligomeric compound in which s is a phosphorothioate nucleoside bond.
[0238] Embodiment 129. Chemical notation below: T ks m C ko G ko G ds U ys T ds Gds G ds A ds A ds T ds T ds m C ds T ko T ks T k An oligomeric compound comprising a modified oligonucleotide according to (SEQ ID NO: 14), wherein, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, U is the uracil nucleic acid base, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, y is the 2'-OMe ribose sugar moiety, s is a phosphorothioate nucleoside bond, An oligomeric compound in which o is a phosphodiester nucleoside bond.
[0239] Embodiment 130. An oligomer compound according to any one of Embodiments 126 to 129, comprising a modified oligonucleotide covalently bonded to a conjugate group.
[0240] Embodiment 131. An oligomeric double chain comprising an oligomeric compound described in any of Embodiments 78 to 130.
[0241] Embodiment 132. An antisense compound comprising, or consisting thereof, an oligomeric compound described in any of Embodiments 78 to 130 or an oligomeric double chain described in Embodiment 131.
[0242] Embodiment 133. A chiralally enriched population of oligonucleotide compounds according to any of Embodiments 117 to 130, wherein the population is enriched with respect to compounds comprising at least one specific phosphorothioate nucleoside bond having a specific stereochemical configuration.
[0243] Embodiment 134. The chiralally enriched population according to Embodiment 133, wherein the population is enriched with respect to a compound comprising at least one specific phosphorothioate nucleoside bond having a (Sp) configuration.
[0244] Embodiment 135. The chiralally enriched population according to Embodiment 133, wherein the population is enriched with respect to a compound comprising at least one specific phosphorothioate nucleoside bond having a (Rp) configuration.
[0245] Embodiment 136. The chiralally enriched population according to Embodiment 133, wherein the population is enriched with respect to compounds having a specific, independently selected stereochemical configuration in each phosphorothioate nucleoside bond.
[0246] Embodiment 137. The chiralally enriched population according to Embodiment 133, wherein the population is enriched with respect to compounds having a (Sp) configuration in each phosphorothioate nucleoside bond, or with respect to modified oligonucleotides having a (Rp) configuration in each phosphorothioate nucleoside bond.
[0247] Embodiment 138. The chiralally enriched population according to Embodiment 133, wherein the population is enriched with respect to compounds having a (Rp) configuration in one specific phosphorothioate nucleoside bond and a (Sp) configuration in each of the remaining phosphorothioate nucleoside bonds.
[0248] Embodiment 139. The chiralally enriched population according to Embodiment 133, wherein the population is enriched with respect to compounds having at least three consecutive phosphorothioate nucleoside bonds in Sp configuration, Sp configuration, and Rp configuration in the 5' to 3' direction.
[0249] Embodiment 140. A group of oligomer compounds according to any one of Embodiments 117 to 130, wherein all of the phosphorothioate nucleoside bonds in the oligomer compound are stereorandom.
[0250] Embodiment 141. A pharmaceutical composition comprising an oligomeric compound according to any of Embodiments 78 to 130, an oligomeric double-chain according to Embodiment 131, an antisense compound according to Embodiment 132, or a group according to any of Embodiments 133 to 140, and a pharmaceutically acceptable carrier or diluent.
[0251] Embodiment 142. A method comprising administering the pharmaceutical composition described in Embodiment 141 to an individual.
[0252] Embodiment 143. A method for treating a disease related to the RAAS pathway, comprising administering a therapeutically effective amount of the pharmaceutical composition described in Embodiment 142 to an individual who has or is at risk of having a disease related to the RAAS pathway, thereby treating the disease related to the RAAS pathway.
[0253] Embodiment 144. The method according to Embodiment 143, wherein the disease is a cardiovascular disease.
[0254] Embodiment 145. The method according to any one of Embodiments 143 and 144, wherein the disease is selected from hypertension, resistant hypertension, Marfan syndrome, heart failure, kidney disease, obesity, metabolic syndrome, NASH, and NAFLD.
[0255] Embodiment 146. The method according to any one of Embodiments 143 to 145, wherein at least one symptom or characteristic of the disease is improved.
[0256] Embodiment 147. The method according to Embodiment 146, wherein the symptom or characteristic is any of the following: hypertension, hypertensive emergency (i.e., malignant hypertension), stroke, pre-eclampsia, vascular aneurysm, abdominal aneurysm, peripheral artery disease, organ injury, or pulmonary hypertension.
[0257] Embodiment 148. The method according to any one of Embodiments 142 to 147, wherein the pharmaceutical composition is administered systemically.
[0258] Embodiment 149. The method according to any one of Embodiments 142 to 148, wherein the pharmaceutical composition is administered subcutaneously or intramuscularly.
[0259] Embodiment 150. Use of an oligomeric compound according to any of Embodiments 78-130, an oligomeric double-chain according to Embodiment 131, an antisense compound according to Embodiment 132, or a population according to any of Embodiments 133-140 to reduce intracellular AGT expression.
[0260] Embodiment 151. The use described in Embodiment 150, which reduces the level of AGT RNA.
[0261] Embodiment 152. The use described in Embodiment 150, which reduces the level of AGT protein.
[0262] I. A specific oligonucleotide In certain embodiments, oligomeric compounds comprising oligonucleotides consisting of linked nucleosides are provided herein. The oligonucleotide may be an unmodified oligonucleotide (RNA or DNA) or a modified oligonucleotide. The modified oligonucleotide comprises at least one modification to the unmodified RNA or DNA. That is, the modified oligonucleotide comprises at least one modified nucleoside (containing a modified sugar moiety and / or a modified nucleic acid base) and / or at least one modified internucleoside bond.
[0263] A. A specific modified nucleoside A modified nucleoside contains either a modified sugar moiety, a modified nucleic acid base, or both a modified sugar moiety and a modified nucleic acid base.
[0264] 1. A specific sugar portion In certain embodiments, the modified sugar moiety is a non-bicyclic modified sugar moiety. In certain embodiments, the modified sugar moiety is a bicyclic or tricyclic sugar moiety. In certain embodiments, the modified sugar moiety is a sugar surrogate. Such a sugar surrogate may include one or more substitutions corresponding to other types of modified sugar moieties.
[0265] In certain embodiments, the modified sugar moiety is a non-bicyclic modified sugar moiety comprising a furanosyl ring having one or more substituents, none of which bridge two atoms of the furanosyl ring to form a bicyclic structure. Such non-bridged substituents may be at any position of the furanosyl ring, including but not limited to substituents at the 2', 4', and / or 5' positions. In certain embodiments, one or more non-bridged substituents of the non-bicyclic modified sugar moiety are branched. Suitable 2'-substituents for the non-bicyclic modified sugar moiety include, but are not limited to, 2'-F, 2'-OCH3 ("OMe" or "O-methyl"), and 2'-O(CH2)2OCH3 ("MOE" or "O-methoxyethyl"). In certain embodiments, the 2'-substituents may be halo, allyl, amino, azide, SH, CN, OCN, CF3, OCF3, O-C1-C 10 Alkoxy, O-C1-C 10 Substitutive alkoxy, O-C1-C 10 Alkyl, O-C1-C 10 Substitutive alkyl, S-alkyl, N(R m )-alkyl, O-alkenyl, S-alkenyl, N(R m )-Alkenyl, O-Alkinyl, S-Alkinyl, N(R m)-Alkynyl, O-Alkyrenyl-O-alkyl, Alkynyl, Alkal, Aralkyl, O-Alkal, O-Aralkyl, O(CH2)2SCH3, O(CH2)2ON(R m )(R n ), or OCH2C(=O)-N(R m )(R n ) are selected from each R m and R n These are independently H, an amino protecting group, or substituted or unsubstituted C1-C 10 The alkyl 2'-substituents are described in Cook et al., US6,531,584, Cook et al., US5,859,221, and Cook et al., US6,005,087. Certain embodiments of these 2'-substituents may be further substituted with one or more substituents independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO2), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl, and alkynyl. Suitable 4'-substituents for the non-bicyclic modified sugar moiety include, but are not limited to, alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO2015 / 106128. Suitable 5'-substituents for the non-bicyclic modified sugar moiety include 5'-methyl (R or S), 5'-vinyl, and 5'-methoxy. In certain embodiments, the non-bicyclic modified sugar moiety comprises two or more non-crosslinked sugar substituents, such as a 2'-F-5'-methyl sugar moiety, as well as modified sugar moieties and modified nucleosides as described in Migawa et al., WO2008 / 101157 and Rajeev et al., US2013 / 0203836.
[0266] In certain embodiments, the 2'-substituted non-bicyclic modified nucleosides are F, NH2, N3, OCF3, OCH3, O(CH2)3NH2, CH2CH=CH2, OCH2CH=CH2, OCH2CH2OCH3, O(CH2)2SCH3, O(CH2)2ON(R m )(R n), O(CH2)2O(CH2)2N(CH3)2, and N-substituted acetamide (OCH2C(=O)-N(R m )(R n The formula comprises a sugar moiety containing a non-crosslinked 2'- substituent selected from )), where each R m and R n These are independently H, an amino protecting group, or substituted or unsubstituted C1-C 10 It is alkyl.
[0267] In certain embodiments, the 2'-substituted non-bicyclic modified nucleoside comprises a sugar moiety containing a non-crosslinked 2'-substituent selected from F, OCF3, OCH3, OCH2CH2OCH3, O(CH2)2SCH3, O(CH2)2ON(CH3)2, O(CH2)2O(CH2)2N(CH3)2, and OCH2C(=O)-N(H)CH3 ("NMA").
[0268] In certain embodiments, the 2'-substituted non-bicyclic modified nucleoside comprises a sugar moiety containing a non-crosslinked 2'-substituent selected from F, OCH3, and OCH2CH2OCH3.
[0269] In certain embodiments, the modified furanosyl sugar moiety and the nucleoside incorporating such modified furanosyl sugar moiety are further defined by their isomer configuration. For example, the 2'-deoxyfuranosyl sugar moiety may have seven isomer configurations other than the naturally occurring β-D-deoxyribosyl configuration. Such modified sugar moieties are described, for example, in WO2019 / 157531, which is incorporated herein by reference. The 2'-modified sugar moiety has an additional stereocenter at the 2'-position compared to the 2'-deoxyfuranosyl sugar moiety; therefore, such a sugar moiety has a total of 16 possible isomer configurations. Unless otherwise specified, the 2'-modified sugar moieties described herein are in the β-D-ribosyl isomer configuration.
[0270] Certain modified sugar moieties include substituents that bridge two atoms of a furanosyl ring, forming a second ring and resulting in a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety includes a bridge between the 4' and 2' furanose ring atoms. Examples of such 4'-to-2' cross-linked sugar substituents include 4'-CH2-2', 4'-(CH2)2-2', 4'-(CH2)3-2', 4'-CH2-O-2' ("LNA"), 4'-CH2-S-2', 4'-(CH2)2-O-2' ("ENA"), 4'-CH(CH3)-O-2' (referred to as "restricted ethyl" or "cEt"), 4'-CH2-O-CH2-2', 4'-CH2-N(R)-2', 4'-CH(CH2OCH3)-O-2' ("restricted MOE" or "cMOE") and their analogues (e.g., Seth et al., US7,399,845, Bhat et al., US7,569,686, Swayze et al., US7,741,457, and Swayze et al. See, for example, al., US8, 022, 193), 4'-C(CH3)(CH3)-O-2' and its analogues (see, for example, Seth et al., US8, 278, 283), 4'-CH2-N(OCH3)-2' and its analogues (see, for example, Prakash et al., US8, 278, 425), 4'-CH2-ON(CH3)-2' (see, for example, Allerson et al., US7, 696, 345 and Allerson et al., US8, 124, 745), 4'-CH2-C(H)(CH3)-2' (see, for example, Zhou, et al., J. Org. Chem., 2009, 74, 118-134), 4'-CH2-C(=CH2)-2' and its analogues (see, for example, Seth et See al., US8, 278, 426), 4'-C(R a R b )-N(R)-O-2',4'-C(R a R b )-ON(R)-2', 4'-CH2-ON(R)-2', and 4'-CH2-N(R)-O-2' (wherein each R, R a , and R b These are independently H, protecting groups, or C1-C 12This includes, but is not limited to, alkyl groups (see, for example, Imanishi et al., US7, 427, 672).
[0271] In a particular embodiment, such 4'~2' crosslinks are independently -[C(R a )(R b )] n -,-[C(R a )(R b )] n -O-, -C(R a )=C(R b )-, -C(Ra)=N-, -C(=NR a )-, -C(=O)-, -C(=S)-, -O-, -Si(R a )2-, -S(=O) x -, and -N(R a )- comprises 1 to 4 bonded groups independently selected from, During the ceremony, x is 0, 1, or 2. n is 1, 2, 3, or 4. Each R a and R b These are independently H, protecting group, hydroxyl, C1-C 12 Alkyl, substituted C1-C 12 Alkyl, C2-C 12 Alkenyl, substituted C2-C 12 Alkenyl, C2-C 12 Alkinyl substitution C2-C 12 Alkinyl, C5-C 20 Aryl, substitution C5-C 20 Aryl, heterocyclic radical, substituted heterocyclic radical, heteroaryl, substituted heteroaryl, C5-C7 alicyclic radical, substituted C5-C7 alicyclic radical, halogen, OJ1, NJ1J2, SJ1, N3, COOJ1, acyl (C(=O)-H), substituted acyl, CN, sulfonyl (S(=O)2-J1), or sulfoxyl (S(=O)-J1), Each J1 and J2 is independent of H, C1-C 12 Alkyl, substituted C1-C 12 Alkyl, C2-C 12Alkenyl, substituted C2-C 12 Alkenyl, C2-C 12 Alkinyl substitution C2-C 12 Alkinyl, C5-C 20 Aryl, substitution C5-C 20 Aryl, acyl (C(=O)-H), substituted acyl, heterocyclic radical, substituted heterocyclic radical, C1-C 12 Aminoalkyl, substituted C1-C 12 It is an aminoalkyl group or a protecting group.
[0272] It is also possible to generate a large amount of nucleic acids in a chemical manner, as described in Freier et al.,Nucleic Acids Research,1997,25(22),4429-4443;Albaek et al.,J.Org.Chem.,2006,71,7731-7740;Singh et al.,Chem.Commun.,1998,4,455-456;Koshkin et al al.,Tetrahedron,1998,54,3607-3630;Kumar et al.,Bioorg.Med.Chem.Lett.,1998,8,2219-2222;Singh et al.,J.Org.Chem.,1998,63,10035-10039;Srivastava et al al.,J.Am.Chem.Soc.,2007,129,8362-8379;Wengel et al.,US7,053,207;Imanishi et al.,US6,268,490;Imanishi et al al.,US6,794,499, Wengel et al.,US6,670,461, Wengel et al.,US7,034,133,Wengel et al.,US8,080,644,Wengel et al.,US8,034,909,Wengel et al.,US8,153,365 al., US7,572,582, Ramasamy et al., US6,525,191, Torsten et al., WO2004 / 106356, Wengel et al., WO1999 / 014226, Seth et al., WO2007 / 134181, Seth et al al.,US7,547,684 Seth et al.,US7,666,854 Seth et al.,US8,088,746 Seth et al.,US7,750,131 Seth et al.,US8,030,467 Seth et al al.,US8,546,556;Seth et al.,USSee also 8,530,640, Migawa et al., US9,012,421, Seth et al., US8,501,805, and U.S. Patent Publications US2008 / 0039618 (Allerson et al.) and US2015 / 0191727 (Migawa et al.).
[0273] In certain embodiments, the bicyclic sugar moiety and the nucleoside incorporating such bicyclic sugar moiety are further defined by their isomer configuration. For example, an LNA nucleoside (as described herein) may be in an α-L configuration or a β-D configuration.
[0274] [ka]
[0275] α-L-methyleneoxy(4'-CH2-O-2') or α-L-LNA bicyclic nucleosides have been incorporated into oligonucleotides that have exhibited antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372). In this specification, the general description of bicyclic nucleosides includes both isomer configurations. When the position of a particular bicyclic nucleoside (e.g., LNA or cEt) is identified in the exemplary embodiments herein, they are in the β-D configuration unless otherwise specified.
[0276] In certain embodiments, the modified sugar moiety comprises one or more non-crosslinked sugar substituents and one or more crosslinked sugar substituents (e.g., 5'-substituted and 4'-2' crosslinked sugars).
[0277] In certain embodiments, the modified sugar moiety is a sugar surrogate. In certain such embodiments, the oxygen atom of the sugar moiety is replaced with, for example, a sulfur, carbon, or nitrogen atom. In certain such embodiments, such modified sugar moiety also includes crosslinked and / or non-crosslinked substituents as described herein. For example, certain sugar surrogates include a 4'-sulfur atom and substitution at the 2' position (see, e.g., Bhat et al., US7,875,733 and Bhat et al., US7,939,677) and / or substitution at the 5' position.
[0278] In certain embodiments, the sugar surrogate comprises a ring having more than five atoms. For example, in certain embodiments, the sugar surrogate comprises a six-membered tetrahydropyran ("THP"). Such tetrahydropyran may be further modified or substituted. Nucleosides comprising such modified tetrahydropyran include, but are not limited to, hexitol nucleic acid ("HNA"), anitol nucleic acid ("ANA"), mannitol nucleic acid ("MNA") (see, e.g., Leumann, CJ. Bioorg. & Med. Chem. 2002, 10, 841-854), fluoroHNA:
[0279] [ka]
[0280] (See "F-HNA," e.g., Swayze et al., US8,088,904, Swayze et al., US8,440,803, Swayze et al., US8,796,437, and Swayze et al., US9,005,906; F-HNA may also be referred to as F-THP or 3'-fluorotetrahydropyran), and a nucleoside comprising an additional modified THP compound having the following formula:
[0281] [ka]
[0282] In the formula, independently, for each of the modified THP nucleosides, Bx is the nucleic acid base portion, T3 and T4 are independently nucleoside-binding groups that bind a modified THP nucleoside to the remainder of the oligonucleotide, or one of T3 and T4 is a nucleoside-binding group that binds a modified THP nucleoside to the remainder of the oligonucleotide, and the other of T3 and T4 is H, a hydroxyl protecting group, a bound conjugate group, or a 5' or 3'-terminal group. q1, q2, q3, q4, q5, q6, and q7 are each independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, or substituted C2-C6 alkynyl. Each of R1 and R2 is independently selected from hydrogen, halogen, substituted or unsubstituted alkoxy, NJ1J2, SJ1, N3, OC(=X)J1, OC(=X)NJ1J2, NJ3C(=X)NJ1J2, and CN, where X is O, S, or NJ1, and each of J1, J2, and J3 is independently H or C1-C6 alkyl.
[0283] In certain embodiments, a modified THP nucleoside is provided, where q1, q2, q3, q4, q5, q6, and q7 are H. In certain embodiments, at least one of q1, q2, q3, q4, q5, q6, and q7 is not H. In certain embodiments, at least one of q1, q2, q3, q4, q5, q6, and q7 is methyl. In certain embodiments, a modified THP nucleoside is provided, where one of R1 and R2 is F. In certain embodiments, R1 is F and R2 is H; in certain embodiments, R1 is methoxy and R2 is H; and in certain embodiments, R1 is methoxyethoxy and R2 is H.
[0284] In certain embodiments, the sugar surrogate comprises a ring having more than five atoms and more than one heteroatom. For example, their use in nucleosides and oligonucleotides containing morpholino sugar moieties has been reported (see, e.g., Braasch et al., Biochemistry, 2002, 41, 4503-4510 and Summerton et al., US5, 698, 685, Summerton et al., US5, 166, 315, Summerton et al., US5, 185, 444, and Summerton et al., US5, 034, 506). As used herein, the term "morpholino" refers to a structure:
[0285] [ka]
[0286] This refers to sugar surrogates that possess [a certain characteristic].
[0287] In certain embodiments, morpholino may be modified, for example, by adding or altering various substituents from the morpholino structure described above. Such sugar surrogates are referred to herein as “modified morpholino”.
[0288] In certain embodiments, the sugar surrogate includes an acyclic moiety. Examples of nucleosides and oligonucleotides containing such acyclic sugar surrogates include, but are not limited to, peptide nucleic acids ("PNA"), acyclic butyl nucleic acids (see, for example, Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., WO2011 / 133876.
[0289] Many other bicyclic and tricyclic sugars, as well as sugar surrogate ring systems, that can be used as modified nucleosides are known in the art.
[0290] 2. Certain modified nucleic acid bases In certain embodiments, the modified oligonucleotide comprises one or more nucleosides containing unmodified nucleic acid bases. In certain embodiments, the modified oligonucleotide comprises one or more nucleosides containing modified nucleic acid bases. In certain embodiments, the modified oligonucleotide comprises one or more nucleosides that do not contain nucleic acid bases, referred to as debased nucleosides.
[0291] In certain embodiments, the modified nucleic acid base is selected from 5-substituted pyrimidines, 6-azapyrimidines, alkyl or alkynyl-substituted pyrimidines, alkyl-substituted purines, and N-2, N-6, and O-6-substituted purines. In certain embodiments, the modified nucleic acid bases are 2-aminopropyladenine, 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyladenine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl(-C≡C-CH3)uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azocymine, 5-ribosyluracil (pseudracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, 8-aza and other 8- Substituted purines, 5-halos, particularly 5-bromo, 5-trifluoromethyl, 5-halouracil, and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, 6-N-benzoyladenine, 2-N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl4-N-benzoylcytosine, 5-methyl4-N-benzoyluracil, universal bases, hydrophobic bases, indiscriminate bases, size-extended bases, and fluorinated bases are selected. Further modified nucleic acid bases include tricyclic pyrimidines such as 1,3-diazaphenoxazine-2-one, 1,3-diazaphenothiazine-2-one, and 9-(2-aminoethoxy)-1,3-diazaphenoxazine-2-one (G-clamp). Modified nucleic acid bases may also include those in which the purine or pyrimidine base is replaced by other heterocycles, such as 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and 2-pyridone.Further nucleic acid bases are disclosed in Merigan et al., US3, 687, 808; The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, JI, Ed., John Wiley & Sons, 1990, 858-859; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; Sanghvi, YS, Chapter 15, Antisense Research and Applications, Crooke, ST and Lebleu, B., Eds., CRC Press, 1993, 273-288; and Chapters 6 and 15, Antisense Drug Technology, Crooke ST, Ed., CRC Press, 2008, 163-166 and 442-443.
[0292] Publications instructing the preparation of the above-mentioned modified nucleic acid bases, as well as certain preparations of other modified nucleic acid bases, include: Manoharan et al., US2003 / 0158403, Manoharan et al., US2003 / 0175906, Dinh et al., US4,845,205, Spielvogel et al., US5,130,302, Rogers et al., US5,134,066, Bischofberger et al., US5,175,273, Urdea et al., US5,367,066, Benner et al., US5,432,272, Matteucci et al., US5,434,257, Gmeiner et al., US5,457,187, Cook et al., US5,459,255, Froehler et al. al.,US5,484,908, Matteucci et al.,US5,502,177, Hawkins et al.,US5,525,711, Haralambidis et al.,US5,552,540, Cook et al.,US5,587,469, Froehler et al.,US5,594,121, Switzer et al. al.,US5,596,091, Cook et al.,US5,614,617, Froehler et al.,US5,645,985, Cook et al.,US5,681,941, Cook et al.,US5,811,534, Cook et al.,US5,750,692, Cook et al. al., US5,948,903, Cook et al. This includes, but is not limited to, the works of al.,US5,587,470, Cook et al.,US5,457,191, Matteucci et al.,US5,763,588, Froehler et al.,US5,830,653, Cook et al.,US5,808,027, Cook et al.,US6,166,199, and Matteucci et al.,US6,005,096.
[0293] 3. Certain modified nucleoside bonds In certain embodiments, the nucleosides of modified oligonucleotides may be linked together using any internucleoside linkage. Two main classes of internucleoside linkages are defined by the presence or absence of a phosphorus atom. Typical phosphorus-containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidates, phosphorothioates ("P(O2)=S"), and phosphorodithioates ("HS-P=S"), which contain phosphodiester links ("P(O2)=O") (also referred to as unmodified or native links). Typical non-phosphorus-containing nucleoside-bonding groups include, but are not limited to, methylenemethylimino (-CH2-N(CH3)-O-CH2-), thiodiesters, thionocarbamates (-OC(=O)(NH)-S-), siloxanes (-O-SiH2-O-), and N,N'-dimethylhydrazine (-CH2-N(CH3)-N(CH3)-). Modified nucleoside-bonding groups can be used to modify, typically increase, the nuclease resistance of oligonucleotides compared to natural phosphodiester nucleoside-bonding groups. In certain embodiments, nucleoside-bonding groups having chiral atoms can be prepared as racemic mixtures or as separate enantiomers. Methods for preparing phosphorus-containing and phosphorus-free nucleoside-bonding groups are well known to those skilled in the art.
[0294] Representative nucleoside bonds having a chiral center include, but are not limited to, alkylphosphonates and phosphorothioates. Modified oligonucleotides containing nucleoside bonds having a chiral center can be prepared as a population of modified oligonucleotides containing stereorandom nucleoside bonds, or as a population of modified oligonucleotides containing phosphorothioate nucleoside bonds in specific stereochemical configurations. In certain embodiments, the population of modified oligonucleotides contains phosphorothioate nucleoside bonds, and all phosphorothioate nucleoside bonds are stereorandom. Such modified oligonucleotides can be produced using synthetic methods that result in a random selection of the stereochemical configuration of each phosphorothioate nucleoside bond. Nevertheless, as will be well understood by those skilled in the art, each individual phosphorothioate of each individual oligonucleotide molecule has a defined stereochemical configuration. In certain embodiments, the population of modified oligonucleotides is enriched with modified oligonucleotides containing one or more specific phosphorothioate nucleoside bonds in specific, independently selected stereochemical configurations. In certain embodiments, a particular arrangement of phosphorothioate nucleoside bonds is present in at least 65% of molecules in the population. In certain embodiments, a particular arrangement of phosphorothioate nucleoside bonds is present in at least 70% of molecules in the population. In certain embodiments, a particular arrangement of phosphorothioate nucleoside bonds is present in at least 80% of molecules in the population. In certain embodiments, a particular arrangement of phosphorothioate nucleoside bonds is present in at least 90% of molecules in the population. In certain embodiments, a particular arrangement of phosphorothioate nucleoside bonds is present in at least 99% of molecules in the population.Such chiralally enriched populations of modified oligonucleotides can be produced using synthetic methods known in the art, e.g., Oka et al., JACS125, 8307 (2003), Wan et al., Nuc. Acid. Res. 42, 13456 (2014), and the methods described in WO2017 / 015555. In certain embodiments, the population of modified oligonucleotides is enriched with modified oligonucleotides having at least one indicated phosphorothioate in the (Sp) configuration. In certain embodiments, the population of modified oligonucleotides is enriched with modified oligonucleotides having at least one phosphorothioate in the (Rp) configuration. In certain embodiments, each modified oligonucleotide containing (Rp) and / or (Sp) phosphorothioates comprises one or more of the following formulas, where "B" represents a nucleic acid base.
[0295] [ka]
[0296] Unless otherwise indicated, the chiral nucleoside bonds of the modified oligonucleotides described herein may be stereorandom or in a specific stereochemical configuration.
[0297] Neutral nucleoside interbonding includes, but is not limited to, phosphotriesters, methylphosphonates, MMI (3'-CH2-N(CH3)-O-5'), amide-3 (3'-CH2-C(=O)-N(H)-5'), amide-4 (3'-CH2-N(H)-C(=O)-5'), formacetal (3'-O-CH2-O-5'), methoxypropyl (MOP), and thioformacetal (3'-S-CH2-O-5'). Further neutral nucleoside bonds include nonionic bonds containing siloxanes (dialkylsiloxanes), carboxylate esters, carboxamides, sulfides, sulfonate esters, and amides (see, for example, *Carbohydrate Modifications in Antisense Research*, YSSanghvi and PDCook, Eds., ACS Symposium Series 580, Chapters 3 and 4, 40-65). Further neutral nucleoside bonds include nonionic bonds containing mixed N, O, S, and CH2 component moieties.
[0298] B. A specific motif In certain embodiments, a modified oligonucleotide comprises one or more modified nucleosides containing a modified sugar moiety. In certain embodiments, a modified oligonucleotide comprises one or more modified nucleosides containing a modified nucleic acid base. In certain embodiments, a modified oligonucleotide comprises one or more modified internucleoside bonds. In such embodiments, the modified, unmodified, and differently modified sugar moieties, nucleic acid bases, and / or internucleoside bonds of the modified oligonucleotide define a pattern or motif. In certain embodiments, the patterns of sugar moieties, nucleic acid bases, and internucleoside bonds are each independent of each other. Thus, a modified oligonucleotide can be described by its sugar motif, nucleic acid base motif, and / or internucleoside bond motif (wherein used herein, the nucleic acid base motif describes a modification to a nucleic acid base that is independent of the sequence of the nucleic acid base).
[0299] 1. A specific sugar motif In certain embodiments, the oligonucleotide comprises one or more modified sugars and / or unmodified sugar moieties arranged along the oligonucleotide or a portion thereof in a defined pattern or sugar motif. In certain examples, such sugar motifs include, but are not limited to, any of the sugar modifications discussed herein.
[0300] In certain embodiments, the modified oligonucleotide has a gapmer motif defined by two external regions or "wings" and a central or internal region or "gap". The three regions of the gapmer motif (5'-wing, gap, and 3'-wing) form a contiguous sequence of nucleosides, where at least a portion of the sugar moieties of each nucleoside in the wings differs from at least a portion of the sugar moieties of the nucleosides in the gap. Specifically, at least the sugar moieties of the nucleosides in each wing closest to the gap (the 3'-side nucleoside of the 5'-wing and the 5'-side nucleoside of the 3'-wing) differ from the sugar moieties of the adjacent gap nucleosides, thus defining the boundary between the wing and the gap (i.e., the wing / gap junction). In certain embodiments, the sugar moieties within the gap are identical to each other. In certain embodiments, the gap comprises one or more nucleosides having sugar moieties that differ from the sugar moieties of one or more other nucleosides in the gap. In certain embodiments, the sugar motifs of the two wings are identical to each other (symmetric gapmer). In certain embodiments, the sugar motif of the 5'-wing is different from the sugar motif of the 3'-wing (asymmetric sugar gapmer).
[0301] In certain embodiments, the gapmer wing contains 1 to 6 nucleosides. In certain embodiments, each nucleoside in each wing of the gapmer contains a modified sugar moiety. In certain embodiments, at least one nucleoside in each wing of the gapmer contains a modified sugar moiety. In certain embodiments, at least two nucleosides in each wing of the gapmer contain a modified sugar moiety. In certain embodiments, at least three nucleosides in each wing of the gapmer contain a modified sugar moiety. In certain embodiments, at least four nucleosides in each wing of the gapmer contain a modified sugar moiety. In certain embodiments, at least five nucleosides in each wing of the gapmer contain a modified sugar moiety.
[0302] In certain embodiments, the gap of the gapmer contains 7 to 12 nucleosides. In certain embodiments, at least 6 nucleosides of the gapmer contain a 2'-β-D-deoxyribosyl sugar moiety. In certain embodiments, each nucleoside of the gapmer contains a 2'-deoxyribosyl sugar moiety. In certain embodiments, each nucleoside of the gapmer contains a 2'-β-D-deoxyribosyl sugar moiety. In certain embodiments, at least 1 nucleoside of the gapmer contains a modified sugar moiety. In certain embodiments, at least 1 nucleoside of the gapmer contains a 2'-OMe sugar moiety.
[0303] In certain embodiments, the gapmer is a deoxygapmer. In certain embodiments, the gap-side nucleoside of each wing / gap junction contains a 2'-deoxyribosyl sugar moiety, and the wing-side nucleoside of each wing / gap junction contains a modified sugar moiety. In certain embodiments, at least six nucleosides of the gapmer's gap contain a 2'-β-D-deoxyribosyl sugar moiety. In certain embodiments, each nucleoside of the gap contains a 2'-deoxyribosyl sugar moiety. In certain embodiments, each nucleoside of each wing of the gapmer contains a modified sugar moiety. In certain embodiments, one nucleoside of the gap contains a modified sugar moiety, and each remaining nucleoside of the gap contains a 2'-deoxyribosyl sugar moiety.
[0304] In certain embodiments, the modified oligonucleotide comprises or consists of a portion having a fully modified sugar motif. In such embodiments, each nucleoside in the fully modified portion of the modified oligonucleotide contains the modified sugar moiety. In certain embodiments, each nucleoside in the entire modified oligonucleotide contains the modified sugar moiety. In certain embodiments, the modified oligonucleotide comprises or consists of a portion having a fully modified sugar motif, and each nucleoside in the fully modified portion contains the same modified sugar moiety, which is referred to herein as the uniformly modified sugar motif. In certain embodiments, the fully modified oligonucleotide is a uniformly modified oligonucleotide. In certain embodiments, each nucleoside in the uniformly modified oligonucleotide contains the same 2'-modification.
[0305] In this specification, the lengths (number of nucleosides) of the three regions of a gapmer may be given using the notation [number of nucleosides in the 5'-wing]-[number of nucleosides in the gap]-[number of nucleosides in the 3'-wing]. Thus, a 5-10-5 gapmer consists of five bound nucleosides in each wing and ten bound nucleosides in the gap. If a specific modification follows such nomenclature, that modification is a modification in each sugar moiety of each wing, and the gap nucleoside consists of a 2'-β-D-deoxyribosyl sugar moiety. Thus, a 5-10-5 MOE gapmer consists of five bound 2'-MOE nucleosides in the 5'-wing, ten bound 2'-β-D-deoxynucleosides in the gap, and five bound 2'-MOE nucleosides in the 3'-wing. The 3-10-3cEt gapmer consists of three bound cEt nucleosides in the 5'-wing, ten bound 2'-β-D-deoxynucleosides in the gap, and three bound cEt nucleosides in the 3'-wing. The 5-8-5 gapmer consists of five bound nucleosides containing a modified sugar moiety in the 5'-wing, eight bound 2'-deoxynucleosides in the gap, and five bound nucleosides containing a modified sugar moiety in the 3'-wing. Mixed-wing gapmers have at least two different modified sugars in the 5' and / or 3' wings. The 5-8-5 or 5-8-4 mixed-wing gapmers have at least two different modified sugar moieties in the 5' and / or 3' wings.
[0306] In certain embodiments, the modified oligonucleotide is a 5-10-5 MOE gapmer. In certain embodiments, the modified oligonucleotide is a 4-10-6 MOE gapmer. In certain embodiments, the modified oligonucleotide is a 6-10-4 MOE gapmer. In certain embodiments, the modified oligonucleotide is a 5-8-5 MOE gapmer. In certain embodiments, the modified oligonucleotide is an XYZ MOE gapmer, where X and Z are independently selected from 1, 2, 3, 4, 5, or 6 linked 2'-MOE nucleosides, and Y is 7, 8, 9, 10, or 11 linked deoxynucleosides.
[0307] In certain embodiments, the modified oligonucleotide has a sugar motif selected from (5' to 3'): meeemddddddddddmmmmm, where 'd' represents the 2'-deoxyribosyl sugar moiety, 'e' represents the 2'-MOE sugar moiety, and 'm' represents the 2'-OMe sugar moiety.
[0308] 2. A specific nucleic acid base motif In certain embodiments, the oligonucleotide comprises modified and / or unmodified nucleic acid bases arranged along the oligonucleotide or a portion thereof in a defined pattern or motif. In certain embodiments, each nucleic acid base is modified. In certain embodiments, none of the nucleic acid bases are modified. In certain embodiments, each purine or each pyrimidine is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each uracil is modified. In certain embodiments, each cytosine is modified. In certain embodiments, some or all of the cytosine nucleic acid bases of the modified oligonucleotide are 5-methylcytosine. In certain embodiments, all of the cytosine nucleic acid bases are 5-methylcytosine, and all of the other nucleic acid bases of the modified oligonucleotide are unmodified nucleic acid bases.
[0309] In certain embodiments, the modified oligonucleotide includes a block of modified nucleic acid bases. In certain such embodiments, the block is located at the 3' end of the oligonucleotide. In certain embodiments, the block is located within 3 nucleosides from the 3' end of the oligonucleotide. In certain embodiments, the block is located at the 5' end of the oligonucleotide. In certain embodiments, the block is located within 3 nucleosides from the 5' end of the oligonucleotide.
[0310] In certain embodiments, the oligonucleotide having a gapmer motif comprises a nucleoside containing a modified nucleic acid base. In certain such embodiments, one nucleoside containing a modified nucleic acid base is located in the central gap of the oligonucleotide having a gapmer motif. In certain such embodiments, the sugar moiety of the nucleoside is a 2'-deoxyribosyl sugar moiety. In certain embodiments, the modified nucleic acid base is selected from 2-thiopyrimidine and 5-propympyrimidine.
[0311] 3. A specific nucleoside bond motif In certain embodiments, the oligonucleotide comprises modified and / or unmodified internucleoside bonds arranged along the oligonucleotide or a portion thereof in a defined pattern or motif. In certain embodiments, each internucleoside bond is a phosphodiester internucleoside bond (P(O2)=O). In certain embodiments, each internucleoside bond in the modified oligonucleotide is a phosphorothioate internucleoside bond (P(O2)=S). In certain embodiments, each internucleoside bond in the modified oligonucleotide is independently selected from phosphorothioate internucleoside bonds and phosphodiester internucleoside bonds. In certain embodiments, each phosphorothioate internucleoside bond is independently selected from stereorandom phosphorothioate, (Sp)phosphorothioate, and (Rp)phosphorothioate. In certain embodiments, the sugar motif of the modified oligonucleotide is a gapmer, and all internucleoside bonds within the gap are modified. In certain such embodiments, some or all of the nucleoside bonds within the wings are unmodified phosphodiester nucleoside bonds. In certain embodiments, the terminal nucleoside bonds are modified. In certain embodiments, the sugar motif of the modified oligonucleotide is a gapmer, and the nucleoside bond motif includes at least one phosphodiester nucleoside bond in at least one wing, where at least one phosphodiester nucleoside bond is not a terminal nucleoside bond, and the remaining nucleoside bonds are phosphorothioate nucleoside bonds. In certain such embodiments, all phosphorothioate nucleoside bonds are stereorandom. In certain embodiments, all phosphorothioate nucleoside bonds in the wings are (Sp)phosphorothioate, and the gap includes at least one Sp,Sp,Rp motif. In certain embodiments, the population of modified oligonucleotides is enriched with modified oligonucleotides containing such nucleoside-linking motifs.
[0312] In a particular embodiment, all nucleoside bonds are either phosphodiester nucleoside bonds or phosphothioate nucleoside bonds, and the chiral motif is (5' to 3'):Sp-ooo-Sp-Sp-Sp-Rp-Sp-Sp-Rp-Sp-Sp-Sp-Sp-Sp-Sp-Sp or Sp-ooo-Sp-Sp-Sp-Rp-Sp-Sp-Sp-Sp-Sp-Sp-Sp-Sp-Sp-Sp-Sp, where each "Sp" represents a (Sp)phosphothioate nucleoside bond, each "Rp" represents an Rp nucleoside bond, and each "o" represents a phosphodiester nucleoside bond. In certain embodiments, the population of modified oligonucleotides is enriched with modified oligonucleotides containing such nucleoside-linking motifs.
[0313] In certain embodiments, the modified oligonucleotide has a sooosssssssssssss nucleoside linkage motif, where each "s" represents a phosphorothioate nucleoside linkage and each "o" represents a phosphodiester nucleoside linkage. In certain embodiments, the modified oligonucleotide has a (5' to 3'): sooooossssssssssss nucleoside linkage motif, where each "s" represents a phosphorothioate nucleoside linkage and each "o" represents a phosphodiester nucleoside linkage. In certain embodiments, the modified oligonucleotide has a (5' to 3'): sooooossssssssssss nucleoside linkage motif, where each "s" represents a phosphorothioate nucleoside linkage and each "o" represents a phosphodiester nucleoside linkage. In certain embodiments, the modified oligonucleotide has a (5' to 3'):sooossssssssssoooss nucleoside linkage motif, where each "s" represents a phosphorothioate nucleoside linkage and each "o" represents a phosphodiester nucleoside linkage. In a particular embodiment, the modified oligonucleotide has a (5' to 3'):sooosssssssssssssss nucleoside linkage motif, where each "s" represents a phosphorothioate nucleoside linkage and each "o" represents a phosphodiester nucleoside linkage.
[0314] C. A specific total length It is possible to increase or decrease the length of oligonucleotides without eliminating their activity. For example, Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992) tested a series of oligonucleotides ranging from 13 to 25 nucleotide lengths for their ability to induce cleavage of target nucleic acids in an oocyte injection model. Oligonucleotides with 25 nucleotide lengths and 8 or 11 mismatched bases near the end were able to induce specific cleavage of target nucleic acids, albeit to a lower degree than oligonucleotides without mismatches. Similarly, target-specific cleavage was achieved using oligonucleotides with 13 nucleotides, including those with one or three mismatches.
[0315] In certain embodiments, oligonucleotides (including modified oligonucleotides) may have any of a range of lengths. In certain embodiments, an oligonucleotide consists of X to Y bound nucleosides, where X represents the minimum number of nucleosides in the range and Y represents the maximum number of nucleosides in the range. In certain such embodiments, X and Y are each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50, provided that X is less than or equal to Y. For example, in a particular embodiment, oligonucleotides are 12-13, 12-14, 12-15, 12-16, 12-17, 12-18, 12-19, 12-20, 12-21, 12-22, 12-23, 12-24, 12-25, 12-26, 12-27, 12-28, 12-29, 12-30, 13-14, 13-15, 13-16, 13-17, 13-18, 13-19, 13-20, 13-21, 13-22, 13-23, 13-24, 13-25, 13-26, 13-27, 13-28, 13-29, 13-30, 14-15, 14-16, 14-17, 14-18, 14-19, 14-20, 14-21, 14-22, 14-23, 14-24, 14-25, 14-26, 14-27, 14-28, 14-29, 14-3 0, 15-16, 15-17, 15-18, 15-19, 15-20, 15-21, 15-22, 15-23, 15-24, 15-25, 15-26, 15-27, 15-28, 15-29, 15-30, 16-17, 16-18, 16-19, 16-20, 16-21, 16-22, 16-23, 16-24, 16-25, 16-26, 16-27, 16-28, 16 ~29, 16~30, 17~18, 17~19, 17~20, 17~21, 17~22, 17~23, 17~24, 17~25, 17~26, 17~27, 17~28, 17~29, 17~30, 18~19, 18~20, 18~21, 18~22, 18~23, 18~24, 18~25, 18~26, 18~27, 18~28, 18~29, 18~30, 19~20,19-21, 19-22, 19-23, 19-24, 19-25, 19-26, 19-29, 19-28, 19-29, 19-30, 20-21, 20-22, 20-23, 20-24, 20-25, 20-26, 20-27, 20-28, 20-29, 20-30, 21-22, 21-23, 21-24, 21-25, 21-26, 21-27, 21-28, 21-29, 21-30, 22-23, 22-24, 22-25, 22-26, 22-27, 2 It consists of 2-28, 22-29, 22-30, 23-24, 23-25, 23-26, 23-27, 23-28, 23-29, 23-30, 24-25, 24-26, 24-27, 24-28, 24-29, 24-30, 25-26, 25-27, 25-28, 25-29, 25-30, 26-27, 26-28, 26-29, 26-30, 27-28, 27-29, 27-30, 28-29, 28-30, or 29-30 bonded nucleosides.
[0316] D. A specific modified oligonucleotide In certain embodiments, the above modifications (sugars, nucleic acid bases, nucleoside bonds) are incorporated into the modified oligonucleotide. In certain embodiments, the modified oligonucleotide is characterized by its modification motif and total length. In certain embodiments, such parameters are independent of each other. Therefore, unless otherwise indicated, each nucleoside bond of an oligonucleotide having a gapmer sugar motif may be modified or unmodified, and may or may not follow the gapmer modification pattern of the sugar modification. For example, the nucleoside bonds in the wing region of a sugar gapmer may be the same or different from each other, and may be the same or different from the nucleoside bonds in the gap region of the sugar motif. Similarly, such a sugar gapmer oligonucleotide may contain one or more modified nucleic acid bases independently of the gapmer pattern of the sugar modification. Unless otherwise indicated, each modification is independent of the nucleic acid base sequence.
[0317] E. A specific group of modified oligonucleotides A population of modified oligonucleotides in which all modified oligonucleotides have the same molecular formula may be a stereorandom population or a chiral-enriched population. All chiral centers of all modified oligonucleotides are stereorandom in a stereorandom population. In a chiral-enriched population, at least one specific chiral center is not stereorandom in the modified oligonucleotides of the population. In certain embodiments, the modified oligonucleotides of a chiral-enriched population are enriched in the β-D-ribosyl sugar moiety, and all phosphorothioate nucleoside bonds are stereorandom. In certain embodiments, the modified oligonucleotides of a chiral-enriched population are enriched in both the β-D-ribosyl sugar moiety and at least one specific phosphorothioate nucleoside bond in a specific stereochemical configuration.
[0318] F. Nucleic acid base sequence In certain embodiments, oligonucleotides (unmodified or modified oligonucleotides) are further described by their nucleic acid base sequences. In certain embodiments, oligonucleotides have a nucleic acid base sequence complementary to an identified reference nucleic acid, such as a second oligonucleotide or target nucleic acid. In certain such embodiments, a portion of the oligonucleotide has a nucleic acid base sequence complementary to an identified reference nucleic acid, such as a second oligonucleotide or target nucleic acid. In certain embodiments, a portion or the entire nucleic acid base sequence of an oligonucleotide is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% complementary to a nucleic acid, such as a second oligonucleotide or target nucleic acid.
[0319] II. Certain Oligomer Compounds In certain embodiments, oligomeric compounds comprising an oligonucleotide (modified or unmodified) and optionally one or more conjugate groups and / or terminal groups are provided herein. A conjugate group comprises one or more conjugate moieties and a conjugate linker that attaches the conjugate moieties to an oligonucleotide. The conjugate group may be attached to either end or both ends and / or any internal position of the oligonucleotide. In certain embodiments, the conjugate group is attached to the 2' position of the nucleoside of the modified oligonucleotide. In certain embodiments, a conjugate group attached to either end or both ends of the oligonucleotide is a terminal group. In certain such embodiments, the conjugate group or terminal group is attached to the 3' end and / or 5' end of the oligonucleotide. In certain such embodiments, the conjugate group (or terminal group) is attached to the 3' end of the oligonucleotide. In certain embodiments, the conjugate group is attached near the 3' end of the oligonucleotide. In certain embodiments, the conjugate group (or terminal group) is attached to the 5' end of the oligonucleotide. In certain embodiments, the conjugate group is attached near the 5' end of the oligonucleotide.
[0320] Examples of terminal groups include, but are not limited to, conjugate groups, capping groups, phosphate moieties, protecting groups, debasic nucleosides, modified or unmodified nucleosides, and two or more independently modified or unmodified nucleosides.
[0321] A. A specific conjugate group In certain embodiments, the oligonucleotide is covalently bonded to one or more conjugate groups. In certain embodiments, the conjugate groups modify one or more properties of the bound oligonucleotide, including, but not limited to, pharmacodynamic properties, pharmacokinetic properties, stability properties, binding properties, absorption properties, tissue distribution properties, cell distribution properties, cell uptake properties, charge properties, and clearance properties. In certain embodiments, the conjugate groups confer new properties to the bound oligonucleotide, such as a fluorophore or reporter group that enables detection of the oligonucleotide. Certain conjugate groups and conjugate moieties have been previously described, for example, the cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), thioethers, for example, hexyl-S-tritylthiol (Manoharan et al., Ann. NYA Acad. Sci., 1992, 660, 306-309, Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), and thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), aliphatic chains, e.g., dodecane-diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118, Kabanov et al., FEBS Lett., 1990, 259, 327-330, Svinarchuk et al., Biochimie, 1993, 75, 49-54), phospholipids, e.g., dihexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654, Shea et al., Nucl. Acids Res.,1990,18,3777-3783), polyamine or polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995,14,969-973), or adamantane acetate palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995,1264,229-237), octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996,277,923-937), tocopherol group (Nishina et al., Molecular Therapy Nucleic Acids, 2015,4,e220, and Nishina et al., Molecular This refers to the Therapy, 2008, 16, 734-740, or the GalNAc cluster (e.g., WO2014 / 179620).
[0322] 1. Conjugate portion The conjugate portion includes, but is not limited to, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates, vitamin portions, polyethylene glycol, thioethers, polyethers, cholesterol, thiocholesterol, cholic acid portions, folic acid, lipids, lipophilic groups, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluorescein, rhodamine, coumarin, fluorophores, and pigments.
[0323] In certain embodiments, the conjugate portion includes an active drug substance, such as aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansyl sarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, benzothiadiazide, chlorothiazide, diazepine, indomethacin, barbiturates, cephalosporins, sulfonamides, antidiabetic drugs, antibacterial agents, or antibiotics.
[0324] 2. Conjugate Linker The conjugate moiety is bonded to the oligonucleotide via a conjugate linker. In certain oligomeric compounds, the conjugate linker is a single chemical bond (i.e., the conjugate moiety is directly bonded to the oligonucleotide via a single bond). In certain oligomeric compounds, the conjugate moiety is bonded to the oligonucleotide via a more complex conjugate linker that contains one or more conjugate linker moieties, which are subunits that make up the conjugate linker. In certain embodiments, the conjugate linker includes a chain structure such as a hydrocarbyl chain, or an oligomer of repeating units such as ethylene glycol, a nucleoside, or an amino acid unit.
[0325] In certain embodiments, the conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain embodiments, the conjugate linker comprises a group selected from alkyl, amino, oxo, amide, and ether groups. In certain embodiments, the conjugate linker comprises a group selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises a group selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker comprises at least one neutral linking group.
[0326] In certain embodiments, conjugate linkers, including the conjugate linker described above, are known in the art to be useful for conjugating a difunctional linkage, for example, a conjugate group to a parent compound such as an oligonucleotide provided herein. Generally, a difunctional linkage includes at least two functional groups. One of the functional groups is selected to bond to a specific site on the parent compound, and the other is selected to bond to a conjugate group. Examples of functional groups used in a difunctional linkage include, but are not limited to, electrophiles for reacting with nucleophiles and nucleophiles for reacting with electrophiles. In certain embodiments, the difunctional linkage includes one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl groups.
[0327] Examples of conjugate linkers include, but are not limited to, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), and 6-aminohexanoic acid (AHEX or AHA). Other conjugate linkers include substituted or unsubstituted C1-C 10 Alkyl, substituted, or unsubstituted C2-C 10 Alkenyl, or substituted or unsubstituted C2-C 10 Alkynnyls are included, and a non-limiting list of preferred substituents includes, but is not limited to, hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, and alkynyl.
[0328] In certain embodiments, the conjugate linker contains 1 to 10 linker nucleosides. In certain embodiments, the conjugate linker contains 2 to 5 linker nucleosides. In certain embodiments, the conjugate linker contains exactly 3 linker nucleosides. In certain embodiments, the conjugate linker contains a TCA motif. In certain embodiments, such linker nucleosides are modified nucleosides. In certain embodiments, such linker nucleosides contain a modified sugar moiety. In certain embodiments, the linker nucleosides are unmodified. In certain embodiments, the linker nucleosides contain an optionally protected heterocyclic base selected from purines, substituted purines, pyrimidines, or substituted pyrimidines. In certain embodiments, the cleavable portion is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine, and 2-N-isobutyrylguanine. It is generally desirable that the linker nucleoside be cleaved from the oligomer compound after reaching the target tissue. Thus, the linker nucleosides are typically linked to each other and to the remainder of the oligomer compound via cleavable bonds. In certain embodiments, such cleavable bonds are phosphodiester bonds.
[0329] In this specification, linker nucleosides are not considered part of oligonucleotides. Therefore, in embodiments in which an oligomeric compound comprises an oligonucleotide consisting of a specific number or range of conjugated nucleosides and / or a specific percentage of complementarity with a reference nucleic acid, and the oligomeric compound also comprises a conjugate group containing a conjugate linker containing a linker nucleoside, these linker nucleosides are not counted in the length of the oligonucleotide and are not used in determining the percentage of complementarity of the oligonucleotide to the reference nucleic acid. For example, an oligomeric compound may comprise (1) a modified oligonucleotide consisting of 8 to 30 nucleosides, and (2) a conjugate group containing 1 to 10 linker nucleosides consecutive with the nucleosides of the modified oligonucleotide. The total number of consecutively conjugated nucleosides in such an oligomeric compound may exceed 30. Alternatively, an oligomeric compound may comprise a modified oligonucleotide consisting of 8 to 30 nucleosides and without a conjugate group. The total number of consecutively bonded nucleosides in such oligomeric compounds is 30 or less. Unless otherwise indicated, the conjugate linker contains 10 or fewer linker nucleosides. In certain embodiments, the conjugate linker contains 5 or fewer linker nucleosides. In certain embodiments, the conjugate linker contains 3 or fewer linker nucleosides. In certain embodiments, the conjugate linker contains 2 or fewer linker nucleosides. In certain embodiments, the conjugate linker contains 1 or fewer linker nucleosides.
[0330] In certain embodiments, it is desirable that the conjugate group be cleaved from the oligonucleotide. For example, in certain circumstances, an oligomeric compound containing a particular conjugate moiety is readily taken up by a particular cell type, but after the oligomeric compound has been taken up, it is desirable that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Therefore, a particular conjugate linker may contain one or more cleavable moieties. In certain embodiments, the cleavable moiety is a cleavable bond. In certain embodiments, the cleavable moiety is an atomic group containing at least one cleavable bond. In certain embodiments, the cleavable moiety contains an atomic group having one, two, three, four, or more than four cleavable bonds. In certain embodiments, the cleavable moiety is selectively cleaved inside a cell or intracellular compartment, such as a lysosome. In certain embodiments, the cleavable moiety is selectively cleaved by an endogenous enzyme, such as a nuclease.
[0331] In certain embodiments, the cleavable bond is selected from amides, esters, ethers, one or both phosphodiesters, phosphate esters, carbamates, or disulfides. In certain embodiments, the cleavable bond is one or both phosphodiesters. In certain embodiments, the cleavable portion includes a phosphate or phosphodiester. In certain embodiments, the cleavable portion is a phosphate or phosphodiester bond between the oligonucleotide and the conjugate moiety or conjugate group.
[0332] In certain embodiments, the cleavable portion comprises or consists of one or more linker nucleosides. In certain such embodiments, one or more linker nucleosides are bonded to each other and / or to the remainder of the oligomeric compound by cleavable bonds. In certain embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain embodiments, the cleavable portion is a 2'-deoxyribonucleoside that is bonded to either the 3' or 5' terminal nucleoside of the oligonucleotide by a phosphodiester nucleoside bond and covalently bonded to the conjugate linker or the remainder of the conjugate portion by a phosphate or phosphorothioate nucleoside bond. In certain such embodiments, the cleavable portion is 2'-deoxyadenosine.
[0333] 3.Cell targeting part In certain embodiments, the conjugate group includes a cell-targeting moiety. In certain embodiments, the conjugate group has the following general formula:
[0334] [ka]
[0335] In the formula, n is between 1 and approximately 3, m is 0 when n is 1, m is 1 when n is 2 or greater, j is 1 or 0, and k is 1 or 0.
[0336] In a particular embodiment, n is 1, j is 1, and k is 0. In a particular embodiment, n is 1, j is 0, and k is 1. In a particular embodiment, n is 1, j is 1, and k is 1. In a particular embodiment, n is 2, j is 1, and k is 0. In a particular embodiment, n is 2, j is 0, and k is 1. In a particular embodiment, n is 2, j is 1, and k is 1. In a particular embodiment, n is 3, j is 1, and k is 0. In a particular embodiment, n is 3, j is 0, and k is 1. In a particular embodiment, n is 3, j is 1, and k is 1.
[0337] In certain embodiments, the conjugate group comprises a cell-targeting moiety having at least one tether ligand. In certain embodiments, the cell-targeting moiety comprises two tether ligands covalently bonded to the branching group. In certain embodiments, the cell-targeting moiety comprises three tether ligands covalently bonded to the branching group.
[0338] B. A specific terminal group In certain embodiments, the oligomeric compound comprises one or more terminal groups. In certain such embodiments, the oligomeric compound comprises a stabilized 5'-phosphate. The stabilized 5'-phosphate comprises 5'-phosphonates, including but not limited to 5'-vinylphosphonates. In certain embodiments, the terminal group comprises one or more debasic nucleosides and / or inverse nucleosides. In certain embodiments, the terminal group comprises one or more 2'-bonded nucleosides. In certain such embodiments, the 2'-bonded nucleosides are debasic nucleosides.
[0339] III. Oligomer double strands In certain embodiments, the oligomeric compounds described herein include oligonucleotides having a nucleic acid base sequence complementary to the sequence of the target nucleic acid. In certain embodiments, the oligomeric compound pairs with a second oligomeric compound to form an oligomeric duplex. Such an oligomeric duplex includes a first oligomeric compound having a portion complementary to the target nucleic acid and a second oligomeric compound having a portion complementary to the first oligomeric compound. In certain embodiments, the first oligomeric compound of the oligomeric duplex includes, or comprises, (1) a modified or unmodified oligonucleotide and optionally a conjugate group, and (2) a second modified or unmodified oligonucleotide and optionally a conjugate group. One or both oligomeric compounds of the oligomeric duplex may include a conjugate group. The oligonucleotides of each oligomeric compound in the oligomeric duplex may include non-complementary overhanging nucleosides.
[0340] IV. Antisense Activation In certain embodiments, oligomeric compounds and oligomeric doubles can impart at least one antisense activity by hybridizing to a target nucleic acid. Such oligomeric compounds and oligomeric doubles are antisense compounds. In certain embodiments, antisense compounds have antisense activity if they reduce the amount or activity of the target nucleic acid by 25% or more in a standard cell assay. In certain embodiments, antisense compounds act selectively on one or more target nucleic acids. Such antisense compounds include nucleic acid sequences that hybridize to one or more target nucleic acids to impart one or more desired antisense activities, and that do not hybridize to one or more non-target nucleic acids or do not hybridize to one or more non-target nucleic acids in a manner that results in significant undesirable antisense activity.
[0341] In certain antisense activities, hybridization of an antisense compound to a target nucleic acid results in the recruitment of a protein that cleaves the target nucleic acid. For example, certain antisense compounds result in RNaseH-mediated cleavage of the target nucleic acid. RNaseH is a cellular endonuclease that cleaves the RNA strand of an RNA:DNA double helix. The DNA in such an RNA:DNA double helix does not need to be unmodified DNA. In certain embodiments, antisense compounds that are sufficiently "DNA-like" to induce RNaseH activity are described herein. In certain embodiments, one or more non-DNA-like nucleosides within the gapmer gap are acceptable.
[0342] In certain antisense activities, the antisense compound or a portion of the antisense compound is incorporated into the RNA-induced silencing complex (RISC), ultimately leading to cleavage of the target nucleic acid. For example, certain antisense compounds result in cleavage of the target nucleic acid by Argonaut. The antisense compound incorporated into RISC is an RNAi compound. RNAi compounds can be double-stranded (siRNA) or single-stranded (ssRNA).
[0343] In certain embodiments, hybridization of an antisense compound to a target nucleic acid does not result in the recruitment of a protein that cleaves the target nucleic acid. In certain embodiments, hybridization of an antisense compound to a target nucleic acid results in a change in the splicing of the target nucleic acid. In certain embodiments, hybridization of an antisense compound to a target nucleic acid results in the inhibition of the binding interaction between the target nucleic acid and a protein or other nucleic acid. In certain embodiments, hybridization of an antisense compound to a target nucleic acid results in a change in the translation of the target nucleic acid.
[0344] Antisense activity can be observed directly or indirectly. In certain embodiments, observation or detection of antisense activity involves observing or detecting changes in the amount of a target nucleic acid or the protein encoded by such target nucleic acid, changes in the ratio of splice variants of the nucleic acid or protein, and / or changes in the phenotype of the cell or subject.
[0345] V. A specific target nucleic acid In certain embodiments, the oligomeric compound comprises or consists of an oligonucleotide containing a portion complementary to the target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid encodes a protein. In certain such embodiments, the target nucleic acid is selected from mature mRNA and pre-mRNA containing introns, exons, and untranslated regions. In certain embodiments, the target nucleic acid is mature mRNA. In certain embodiments, the target nucleic acid is pre-mRNA. In certain embodiments, the target region is entirely within an intron. In certain embodiments, the target region spans an intron / exon junction. In certain embodiments, at least 50% of the target region is within an intron.
[0346] A. Complementarity / mismatch with target nucleic acid It is possible to introduce mismatched bases without losing activity. For example, Gautschi et al (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of an oligonucleotide with 100% complementarity to bcl-2 mRNA and three mismatches to bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and in vivo. Furthermore, this oligonucleotide also showed potent antitumor activity in vivo. Maher and Dolnick (Nuc. Acid. Res. 16:3341-3358, 1988) tested a series of tandem 14-nucleotide oligonucleotides, as well as 28 and 42-nucleotide oligonucleotides composed of two or three sequences of the tandem oligonucleotides, for their ability to halt human DHFR translation in a rabbit reticulocyte assay. Each of the three 14-nucleotide oligonucleotides could inhibit translation individually, albeit at a more moderate level than the 28- or 42-nucleotide oligonucleotides.
[0347] In certain embodiments, the oligonucleotide is complementary to the target nucleic acid over its entire length. In certain embodiments, the oligonucleotide is 99%, 95%, 90%, 85%, or 80% complementary to the target nucleic acid. In certain embodiments, the oligonucleotide is at least 80% complementary to the target nucleic acid over its entire length and includes portions that are 100% or completely complementary to the target nucleic acid. In certain embodiments, the completely complementary portions are 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 nucleic acid base lengths.
[0348] In certain embodiments, the oligonucleotide contains one or more mismatched nucleic acid bases with respect to the target nucleic acid. In certain embodiments, the antisense activity against the target is reduced by such mismatch, but the activity against non-targets is reduced to a greater extent. Thus, in certain embodiments, the selectivity of the oligonucleotide is improved. In certain embodiments, the mismatch is specifically located within the oligonucleotide having a gapmer motif. In certain embodiments, the mismatch is located at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 from the 5' end of the gap region. In certain embodiments, the mismatch is located at positions 1, 2, 3, 4, 5, or 6 from the 5' end of the 5' wing region or 3' wing region.
[0349] B.AGT In certain embodiments, the oligomeric compound comprises or consists of an oligonucleotide complementary to the target nucleic acid, the target nucleic acid being an AGT nucleic acid. In certain embodiments, the AGT nucleic acid has the sequence shown in SEQ ID NO: 1 (GENBANK accession number NM_000029.3) or SEQ ID NO: 2 (complementary to GENBANK accession number NC_000001.11, with nucleotides 230700001-230718000 cleaved).
[0350] In certain embodiments, the amount of AGT RNA is reduced by contacting cells with an oligomeric compound complementary to either SEQ ID NOs: 1 and 2, and in certain embodiments, the amount of AGT protein is reduced. In certain embodiments, the oligomeric compound consists of a modified oligonucleotide. In certain embodiments, the amount of intracellular AGT RNA is reduced by contacting cells with an oligomeric compound complementary to either SEQ ID NOs: 1 and 2, and in certain embodiments, the amount of intracellular AGT protein is reduced. In certain embodiments, the cells are in vitro. In certain embodiments, the cells are within a subject. In certain embodiments, the oligomeric compound consists of a modified oligonucleotide. In certain embodiments, one or more symptoms or characteristics of cardiovascular disease are improved by contacting cells within a subject with an oligomeric compound complementary to either SEQ ID NOs: 1 and 2. In certain embodiments, the disease is hypertension. In certain embodiments, the disease is resistant hypertension. In certain embodiments, the disease is Marfan syndrome. In certain embodiments, the disease is heart failure. In certain embodiments, the symptoms or characteristics are selected from hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, vascular aneurysm, peripheral artery disease, and organ injury.
[0351] In certain embodiments, an oligomeric compound complementary to either SEQ ID NO: 1 or 2 can reduce the amount of AGT RNA detectable in vitro by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% when administered according to a standard cell assay. In certain embodiments, an oligomeric compound complementary to SEQ ID NO: 1 or 2 can reduce the amount of AGT in vitro by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% when administered according to a standard in vitro assay. In certain embodiments, an oligomeric compound complementary to SEQ ID NO: 1 or 2 can reduce the amount of AGT RNA detectable in a subject by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
[0352] VI. A specific conjugated compound In certain embodiments, the oligomeric compounds described herein comprise or consist of an oligonucleotide (modified or unmodified) and optionally one or more conjugate groups and / or terminal groups. A conjugate group comprises one or more conjugate moieties and a conjugate linker that attaches the conjugate moieties to an oligonucleotide. The conjugate group may be attached to either end or both ends and / or any internal position of the oligonucleotide. In certain embodiments, the conjugate group is attached to the 2' position of the nucleoside of the modified oligonucleotide. In certain embodiments, a conjugate group attached to either end or both ends of the oligonucleotide is a terminal group. In certain such embodiments, the conjugate group or terminal group is attached to the 3' end and / or 5' end of the oligonucleotide. In certain such embodiments, the conjugate group (or terminal group) is attached to the 3' end of the oligonucleotide. In certain embodiments, the conjugate group is attached near the 3' end of the oligonucleotide. In certain embodiments, the conjugate group (or terminal group) is attached to the 5' end of the oligonucleotide. In certain embodiments, the conjugate group is attached near the 5' end of the oligonucleotide.
[0353] In certain embodiments, the oligonucleotide is modified. In certain embodiments, the oligonucleotide of the compound has a nucleic acid base sequence complementary to the target nucleic acid. In certain embodiments, the oligonucleotide is complementary to messenger RNA (mRNA). In certain embodiments, the oligonucleotide is complementary to pre-mRNA. In certain embodiments, the oligonucleotide is complementary to the sense transcript.
[0354] Examples of terminal groups include, but are not limited to, conjugate groups, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more independently modified or unmodified nucleosides. In certain embodiments, the oligonucleotide is covalently bonded to one or more conjugate groups. In certain embodiments, the conjugate groups modify one or more properties of the conjugated oligonucleotide, including, but not limited to, pharmacodynamic properties, pharmacokinetic properties, stability properties, binding properties, absorption properties, tissue distribution properties, cell distribution properties, cell uptake properties, charge properties, and clearance properties. In certain embodiments, the conjugate groups confer new properties to the conjugated oligonucleotide, such as a fluorophore or reporter group that enables detection of the oligonucleotide. Certain conjugate groups and conjugate moieties have been previously described, for example, the cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), thioethers, for example, hexyl-S-tritylthiol (Manoharan et al., Ann. NY Acad. Sci., 1992, 660, 306-309, Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), and thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), aliphatic chains, e.g., dodecane-diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118, Kabanov et al., FEBS Lett., 1990, 259, 327-330, Svinarchuk et al., Biochimie, 1993, 75, 49-54), phospholipids, e.g., dihexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654, Shea et al., Nucl. Acids Res.,1990,18,3777-3783), polyamine or polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995,14,969-973), or adamantane acetate palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995,1264,229-237), octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996,277,923-937), tocopherol group (Nishina et al., Molecular Therapy Nucleic Acids, 2015,4,e220, and Nishina et al., Molecular This refers to the Therapy, 2008, 16, 734-740, or the GalNAc cluster (e.g., WO2014 / 179620).
[0355] 1. Conjugate portion The conjugate moiety may include, but is not limited to, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates (e.g., GalNAc), vitamin moieties, polyethylene glycol, thioethers, polyethers, cholesterol, thiocholesterol, cholic acid moieties, folic acid, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluorescein, rhodamine, coumarin, fluorophores, and pigments.
[0356] In certain embodiments, the conjugate portion includes an active drug substance, such as aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansyl sarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, benzothiadiazide, chlorothiazide, diazepine, indomethacin, barbiturates, cephalosporins, sulfonamides, antidiabetic drugs, antibacterial agents, or antibiotics.
[0357] 2. Conjugate Linker The conjugate moiety is bonded to the oligonucleotide via a conjugate linker. In certain compounds, the conjugate linker is a single chemical bond (i.e., the conjugate moiety is directly bonded to the oligonucleotide via a single bond). In certain compounds, the conjugate moiety is bonded to the oligonucleotide via a more complex conjugate linker that contains one or more conjugate linker moieties, which are subunits that make up the conjugate linker. In certain embodiments, the conjugate linker includes a chain structure such as a hydrocarbyl chain, or an oligomer of repeating units such as ethylene glycol, a nucleoside, or an amino acid unit.
[0358] In certain embodiments, the conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain embodiments, the conjugate linker comprises a group selected from alkyl, amino, oxo, amide, and ether groups. In certain embodiments, the conjugate linker comprises a group selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises a group selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker comprises at least one neutral linking group.
[0359] In certain embodiments, conjugate linkers, including the conjugate linker described above, are known in the art to be useful for conjugating a difunctional linkage, for example, a conjugate group, to a parent compound such as an oligonucleotide provided herein. Generally, a difunctional linkage includes at least two functional groups. One of the functional groups is selected to bond to a specific site on the parent compound, and the other is selected to bond to a conjugate group. Examples of functional groups used in a difunctional linkage include, but are not limited to, electrophiles for reacting with nucleophiles and nucleophiles for reacting with electrophiles. In certain embodiments, the difunctional linkage includes one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl groups.
[0360] Examples of conjugate linkers include, but are not limited to, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), and 6-aminohexanoic acid (AHEX or AHA). Other conjugate linkers include substituted or unsubstituted C1-C 10 Alkyl, substituted, or unsubstituted C2-C 10 Alkenyl, or substituted or unsubstituted C2-C 10 Alkynnyls are included, and a non-limiting list of preferred substituents includes, but is not limited to, hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, and alkynyl.
[0361] In certain embodiments, the conjugate linker contains 1 to 10 linker nucleosides. In certain embodiments, such linker nucleosides are modified nucleosides. In certain embodiments, such linker nucleosides contain a modified sugar moiety. In certain embodiments, the linker nucleosides are unmodified. In certain embodiments, the linker nucleosides contain an optionally protected heterocyclic base selected from purines, substituted purines, pyrimidines, or substituted pyrimidines. In certain embodiments, the cleavable moieties are nucleosides selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine, and 2-N-isobutyrylguanine. Typically, it is desirable that the linker nucleosides be cleaved from the compound after reaching the target tissue. Therefore, linker nucleosides are typically linked to each other and to the remainder of the compound via cleavable bonds. In certain embodiments, such cleavable bonds are phosphodiester bonds.
[0362] In this specification, linker nucleosides are not considered part of oligonucleotides. Therefore, in embodiments where a compound comprises an oligonucleotide consisting of a specific number or range of conjugated nucleosides and / or a specific percentage of complementarity with a reference nucleic acid, and where the compound comprises a conjugate group containing a conjugate linker with linker nucleosides, those linker nucleosides are not counted in the length of the oligonucleotide and are not used in determining the percentage of complementarity of the oligonucleotide to the reference nucleic acid. For example, a compound may comprise (1) a modified oligonucleotide consisting of 8 to 30 nucleosides, and (2) a conjugate group containing 1 to 10 linker nucleosides consecutively with the nucleosides of the modified oligonucleotide. The total number of consecutively conjugated nucleosides in such a compound is greater than 30. Alternatively, a compound may comprise a modified oligonucleotide consisting of 8 to 30 nucleosides and without a conjugate group. The total number of consecutively conjugated nucleosides in such a compound is 30 or less. Unless otherwise indicated, the conjugate linker contains 10 or fewer linker nucleosides. In certain embodiments, the conjugate linker contains 5 or fewer linker nucleosides. In certain embodiments, the conjugate linker contains 3 or fewer linker nucleosides. In certain embodiments, the conjugate linker contains 2 or fewer linker nucleosides. In certain embodiments, the conjugate linker contains 1 or fewer linker nucleosides.
[0363] In certain embodiments, it is desirable that the conjugate group be cleaved from the oligonucleotide. For example, in certain circumstances, it is desirable that a compound containing a particular conjugate moiety be taken up by a particular cell type, but once the compound is taken up, the conjugate group be cleaved to release the unconjugated oligonucleotide or parent oligonucleotide. Therefore, a particular conjugate linker may contain one or more cleavable moieties. In certain embodiments, the cleavable moiety is a cleavable bond. In certain embodiments, the cleavable moiety is an atomic group containing at least one cleavable bond. In certain embodiments, the cleavable moiety contains an atomic group having one, two, three, four, or more than four cleavable bonds. In certain embodiments, the cleavable moiety is selectively cleaved inside a cell or intracellular compartment, such as a lysosome. In certain embodiments, the cleavable moiety is selectively cleaved by an endogenous enzyme, such as a nuclease.
[0364] In certain embodiments, the cleavable bond is selected from amides, esters, ethers, one or both phosphodiesters, phosphate esters, carbamates, or disulfides. In certain embodiments, the cleavable bond is one or both phosphodiesters. In certain embodiments, the cleavable portion includes phosphate or a phosphodiester. In certain embodiments, the cleavable portion is a phosphate bond between the oligonucleotide and the conjugate moiety or conjugate group.
[0365] In certain embodiments, the cleavable portion comprises or consists of one or more linker nucleosides. In certain such embodiments, one or more linker nucleosides are bonded to each other and / or to the remainder of the compound by cleavable bonds. In certain embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain embodiments, the cleavable portion is a 2'-deoxynucleoside, bonded to either the 3'-terminal nucleoside or the 5'-terminal nucleoside of the oligonucleotide by a phosphate nucleoside bond and covalently bonded to the conjugated linker or the remainder of the conjugated portion by a phosphate or phosphorothioate bond. In certain such embodiments, the cleavable portion is 2'-deoxyadenosine.
[0366] 3. A specific cell-targeting conjugate portion. In certain embodiments, the conjugate group includes a cell-targeting conjugate moiety. In certain embodiments, the conjugate group has the following general formula:
[0367] [ka]
[0368] In the formula, n is between 1 and approximately 3, m is 0 when n is 1, m is 1 when n is 2 or greater, j is 1 or 0, and k is 1 or 0.
[0369] In a particular embodiment, n is 1, j is 1, and k is 0. In a particular embodiment, n is 1, j is 0, and k is 1. In a particular embodiment, n is 1, j is 1, and k is 1. In a particular embodiment, n is 2, j is 1, and k is 0. In a particular embodiment, n is 2, j is 0, and k is 1. In a particular embodiment, n is 2, j is 1, and k is 1. In a particular embodiment, n is 3, j is 1, and k is 0. In a particular embodiment, n is 3, j is 0, and k is 1. In a particular embodiment, n is 3, j is 1, and k is 1.
[0370] In certain embodiments, the conjugate group comprises a cell-targeting moiety having at least one tether ligand. In certain embodiments, the cell-targeting moiety comprises two tether ligands covalently bonded to the branching group. In certain embodiments, the cell-targeting moiety comprises three tether ligands covalently bonded to the branching group.
[0371] In certain embodiments, the cell-targeting moiety includes a branched group comprising one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino groups. In certain embodiments, the branched group includes a branched aliphatic group comprising a group selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino groups. In certain embodiments, the branched aliphatic group comprises a group selected from alkyl, amino, oxo, amide, and ether groups. In certain embodiments, the branched aliphatic group comprises a group selected from alkyl, amino, and ether groups. In certain embodiments, the branched aliphatic group comprises a group selected from alkyl and ether groups. In certain embodiments, the branched group comprises a monocyclic or polycyclic ring system.
[0372] In certain embodiments, each tether of the cell-targeting moiety comprises one or more groups selected from alkyl, substituted alkyl, ether, thioether, disulfide, amino, oxo, amide, phosphodiester, and polyethylene glycol in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, ether, thioether, disulfide, amino, oxo, amide, and polyethylene glycol in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, phosphodiester, ether, amino, oxo, and amide in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, ether, amino, oxo, and amide in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, amino, and oxo in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl and oxo in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl and phosphodiester in any combination. In certain embodiments, each tether comprises at least one phosphorus linking group or neutral linking group. In certain embodiments, each tether comprises a chain with a length of about 6 to about 20 atoms. In certain embodiments, each tether comprises a chain with a length of about 10 to about 18 atoms. In certain embodiments, each tether comprises a chain length of about 10 atoms.
[0373] In certain embodiments, each ligand in the cell-targeting moiety has affinity for at least one receptor type on the target cell. In certain embodiments, each ligand has affinity for at least one receptor type on the surface of mammalian liver cells. In certain embodiments, each ligand has affinity for the hepatic glycoprotein receptor (ASGP-R). In certain embodiments, each ligand is a carbohydrate. In certain embodiments, each ligand is independently selected from galactose, N-acetylgalactosamine (GalNAc), mannose, glucose, glucosamine, and fucose. In certain embodiments, each ligand is N-acetylgalactosamine (GalNAc). In certain embodiments, the cell-targeting moiety comprises three GalNAc ligands. In certain embodiments, the cell-targeting moiety comprises two GalNAc ligands. In certain embodiments, the cell-targeting moiety comprises one GalNAc ligand.
[0374] In certain embodiments, each ligand in the cell-targeting moiety is a carbohydrate, carbohydrate derivative, modified carbohydrate, polysaccharide, modified polysaccharide, or polysaccharide derivative. In certain such embodiments, the conjugate group comprises a carbohydrate cluster (see, for example, Maier et al., “Synthesis of Antisense Oligonucleotides Conjugated to a Multivalent Carbohydrate Cluster for Cellular Targeting,” Bioconjugate Chemistry, 2003, 14, 18-29 or Rensen et al., “Design and Synthesis of Novel N-Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asiaglycoprotein Receptor,” J.Med.Chem. 2004, 47, 5798-5808). In certain such embodiments, each ligand is an amino sugar or a thio sugar. For example, amino sugars can be selected from any number of compounds known in the art, such as sialic acid, α-D-galactosamine, β-muramic acid, 2-deoxy-2-methylamino-L-glucopyranose, 4,6-dideoxy-4-formamido-2,3-di-O-methyl-D-mannopyranose, 2-deoxy-2-sulfamino-D-glucopyranose and N-sulfo-D-glucosamine, and N-glycoyl-α-neuraminic acid. For example, thiosugars can be selected from 5-thio-β-D-glucopyranose, methyl 2,3,4-tri-O-acetyl-1-thio-6-O-trityl-α-D-glucopyranose, 4-thio-β-D-galactopyranose, and ethyl 3,4,6,7-tetra-O-acetyl-2-deoxy-1,5-dithio-α-D-gluco-heptopyranoside.
[0375] In a particular embodiment, the conjugate group is given by the following formula:
[0376] [ka]
[0377] It contains a cell-targeting portion.
[0378] In a particular embodiment, the conjugate group is given by the following formula:
[0379] [ka]
[0380] It contains a cell-targeting portion.
[0381] In a particular embodiment, the conjugate group is given by the following formula:
[0382] [ka]
[0383] It contains a cell-targeting portion.
[0384] In a particular embodiment, the conjugate group is given by the following formula:
[0385] [ka]
[0386] It contains a cell-targeting portion.
[0387] In a particular embodiment, the conjugate group is given by the following formula:
[0388] [ka]
[0389] It contains a cell-targeting portion.
[0390] In certain embodiments, the compound comprises a conjugate group described herein as "LICA-1". LICA-1 has the following formula:
[0391] [ka]
[0392] It holds. In certain embodiments, the compounds described herein include LICA-1, and the cleavable portion within the conjugate linker is of the following formula:
[0393] [ka]
[0394] It has, In the formula, "oligo" refers to an oligonucleotide.
[0395] Representative U.S. patents, U.S. patent application publications, international patent application publications, and other publications that teach specific preparations of compounds including the above-mentioned conjugate groups, conjugate groups, tethers, conjugate linkers, branched groups, ligands, cleavable moieties, and other modifications include U.S. 5,994,517, U.S. 6,300,319, U.S. 6,660,720, U.S. 6,906,182, U.S. 7,262,177, U.S. 7,491,805, U.S. 8,106,022, U.S. 7,723,509, U.S. 2006 / 0148740, U.S. 2011 / 0123520, U.S. 2013 / 033230, and U.S. 2012 / 037254, Biessen et al., J. Med. Chem. 1995, 38, 1846-1852, Lee et al. This includes, but is not limited to, *al., Bioorganic & Medicinal Chemistry 2011, 19, 2494-2500*, *Rensen et al., J. Biol. Chem. 2001, 276, 37577-37584*, *Rensen et al., J. Med. Chem. 2004, 47, 5798-5808*, *Sliedregt et al., J. Med. Chem. 1999, 42, 609-618*, and *Valentijn et al., Tetrahedron, 1997, 53, 759-770*.
[0396] In certain embodiments, the modified oligonucleotide comprises a gapmer or a fully modified sugar motif and a conjugate group containing at least one, two, or three GalNAc ligands. In certain embodiments, the compound is referenced in the following references: Lee, Carbohydr Res, 1978, 67, 509-514; Connolly et al., J Biol Chem, 1982, 257, 939-945; Pavia et al., Int J Pep Protein Res, 1983, 22, 539-548; Lee et al., Biochem, 1984, 23, 4255-4261; Lee et al., Glycoconjugate J, 1987, 4, 317-328; Toyokuni et al., Tetrahedron Lett, 1990, 31, 2673-2676; Biessen et al., J Med Chem, 1995, 38, 1538-1546; Valentijn et al. al., Tetrahedron,1997,53,759-770, Kim et al., Tetrahedron Lett,1997,38,3487-3490, Lee et al.,Bioconjug Chem,1997,8,762-765, Kato et al.,Glycobiol,2001,11,821-829, Rensen et al. al., J Biol Chem,2001,276,37577-37584, Lee et al.,Methods Enzymol,2003,362,38-43, Westerlind et al.,Glycoconj J,2004,21,227-241, Lee et al.,Bioorg Med Chem Lett,2006,16(19),5132-5135, Maierhofer et al.,Bioorg Med Chem,2007,15,7661-7676, Khorev et al.,Bioorg Med Chem,2008,16,5216-5231, Lee et al.,Bioorg Med Chem,2011,19,2494-2500,Kornilova et al.,Analyt Biochem,2012,425,43-46,Pujol et al.,Angew Chemie Int Ed Engl,2012,51,7445-7448、Biessen et al.,J Med Chem,1995,38,1846-1852、Sliedregt et al.,J Med Chem,1999,42,609-618、Rensen et al.,J Med. Chem,2004,47,5798-5808、Rensen et al.,Arterioscler Thromb Vasc Biol,2006,26,169-175、van Rossenberg et al.,Gene Ther,2004,11,457-464、Sato et al.,J Am Chem. Soc,2004,126,14013-14022、Lee et al.,J Org Chem,2012,77,7564-7571、Biessen et al.,FASEB J,2000,14,1784-1792、Rajur et al.,Bioconjug Chem,1997,8,935-940、Duff et al.,Methods Enzymol,2000,313,297-321、Maier et al.,Bioconjug Chem,2003,14,18-29、Jayaprakash et al.,Org Lett,2010,12,5410-5413、Manoharan,Antisense Nucleic Acid Drug Dev,2002,12,103-128、Merwin et al.,Bioconjug Chem,1994,5,612-620、Tomiya et al.,Chem Bioorg,20135275-5281, International applications WO1998 / 013381, WO2011 / 038356, WO1997 / 046098, WO2008 / 098788, WO2004 / 101619, WO2012 / 037254, WO2011 / 120053, WO2011 / 100131, WO2011 / 163121, WO2012 / 177947, WO2013 / 033230, WO2013 / 075035, WO 2012 / 083185, WO2012 / 083046, WO2009 / 082607, WO2009 / 134487, WO2010 / 144740, WO2010 / 148013, WO1997 / 020 563, WO2010 / 088537, WO2002 / 043771, WO2010 / 129709, WO2012 / 068187, WO2009 / 126933, WO2004 / 024757, WO Nos. 2010 / 054406, WO2012 / 089352, WO2012 / 089602, WO2013 / 166121, WO2013 / 165816, U.S. Nos. 4,751,219, 8,552,163, 6,908,903, 7,262,177, 5,994,517, 6,300,319, 8,106,022, 7,491,805, 7,491,805, 7,582,744, 8,137 , 695, 6,383,812, 6,525,031, 6,660,720, 7,723,509, 8,541,548, 8,344,125, 8,313,772, 8,349,308, No. 8,450,467, No. 8,501,930, No. 8,158,601, No. 7,262,177, No. 6,906,182, No. 6,620,916, No. 8,435,491, No. 8,404,862, No. 7,851,615, Published U.S. Patent Applications US2011 / 0097264, US2011 / 0097265, US2013 / 0004427, US2005 / 0164235, US2006 / 0148740, US2008 / 0281044, US2010 / 0240730, US200 Issues 3 / 0119724, US2006 / 0183886, US2008 / 0206869, US2011 / 0269814, US2009 / 0286973, US2011 / 0207799, US2012 / 0136042, US2012 / 0165393, and US2008 / 02810 41, US2009 / 0203135, US2012 / 0035115, US2012 / 0095075, US2012 / 0101148 , US2012 / 0128760, US2012 / 0157509, US2012 / 0230938, US2013 / 0109817, U It contains a conjugate group found in any of the following publications: S2013 / 0121954, US2013 / 0178512, US2013 / 0236968, US2011 / 0123520, US2003 / 0077829, US2008 / 0108801, and US2009 / 0203132.
[0397] VII. Certain Pharmaceutical Compositions In certain embodiments, a pharmaceutical composition comprising one or more oligomeric compounds is provided herein. In certain embodiments, each of the one or more oligomeric compounds comprises a modified oligonucleotide. In certain embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable diluent or carrier. In certain embodiments, the pharmaceutical composition comprises or comprises a saline solution and one or more oligomeric compounds. In certain embodiments, the pharmaceutical composition comprises or comprises sterile saline and one or more oligomeric compounds. In certain embodiments, the sterile saline is pharmaceutical-grade saline. In certain embodiments, the pharmaceutical composition comprises or comprises one or more oligomeric compounds and water. In certain embodiments, the pharmaceutical composition comprises one or more oligomeric compounds and sterile water. In certain embodiments, the sterile water is pharmaceutical-grade water. In certain embodiments, the pharmaceutical composition comprises or comprises one or more oligomeric compounds and phosphate-buffered saline (PBS). In certain embodiments, the sterile PBS comprises pharmaceutical-grade PBS.
[0398] In certain embodiments, the pharmaceutical composition comprises one or more oligomeric compounds and one or more excipients. In certain embodiments, the excipients are selected from water, saline solution, alcohol, polyethylene glycol, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, and polyvinylpyrrolidone.
[0399] In certain embodiments, the oligomeric compound may be mixed with pharmaceutically acceptable active and / or inactive substances for the preparation of a pharmaceutical composition or formulation. The compositions and methods for formulating the pharmaceutical composition depend on several criteria, including but not limited to the route of administration, the severity of the disease, or the dose administered.
[0400] In certain embodiments, a pharmaceutical composition comprising an oligomeric compound includes any pharmaceutically acceptable salt of the oligomeric compound, an ester of the oligomeric compound, or a salt of such an ester. In certain embodiments, a pharmaceutical composition comprising an oligomeric compound comprising one or more oligonucleotides can, when administered to a subject including a human, (directly or indirectly) deliver a biologically active metabolite or its residue. Thus, for example, this disclosure also covers pharmaceutically acceptable salts of oligomeric compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Preferred pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts. In certain embodiments, a prodrug comprises one or more conjugate groups bonded to an oligonucleotide, which are cleaved by endogenous nucleases in the body.
[0401] Lipid moieties are used in nucleic acid therapy in various ways. In certain such methods, nucleic acids, such as oligomeric compounds, are introduced into pre-formed liposomes or lipoplexes prepared from a mixture of cationic and neutral lipids. In certain methods, DNA complexes with mono- or polycationic lipids are formed in the absence of neutral lipids. In certain embodiments, lipid moieties are selected to increase the distribution of a pharmaceutical agent to specific cells or tissues. In certain embodiments, lipid moieties are selected to increase the distribution of a pharmaceutical agent to adipose tissue. In certain embodiments, lipid moieties are selected to increase the distribution of a pharmaceutical agent to muscle tissue.
[0402] In certain embodiments, the pharmaceutical composition includes a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions that include hydrophobic compounds. In certain embodiments, certain organic solvents, such as dimethyl sulfoxide, are used.
[0403] In certain embodiments, the pharmaceutical composition comprises one or more tissue-specific delivery molecules designed to deliver one or more pharmaceutical agents, each containing an oligomeric compound provided herein, to a specific tissue or cell type. For example, in certain embodiments, the pharmaceutical composition comprises liposomes coated with a tissue-specific antibody.
[0404] In certain embodiments, the pharmaceutical composition includes a cosolvent system. Certain such cosolvent systems include, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such cosolvent systems are used for hydrophobic compounds. A non-limiting example of such a cosolvent system is the VPD cosolvent system, which is a solution of anhydrous ethanol containing 3% w / v benzyl alcohol, 8% w / v nonpolar surfactant Polysorbate 80™, and 65% w / v polyethylene glycol 300. The proportions of such cosolvent systems can vary considerably without significantly altering their solubility and toxicity properties. Furthermore, the identity of the cosolvent components may vary; for example, other surfactants may be used instead of Polysorbate 80™, the fraction size of polyethylene glycol may vary, other biocompatible polymers may replace polyethylene glycol, such as polyvinylpyrrolidone, and other sugars or polysaccharides may replace dextrose.
[0405] In certain embodiments, the pharmaceutical composition is prepared for oral administration. In certain embodiments, the pharmaceutical composition is prepared for oral administration. In certain embodiments, the pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, intrathecal (IT), intraventricular (ICV), intraneuronal, perineurial, etc.). In certain such embodiments, the pharmaceutical composition comprises a carrier and is formulated in an aqueous solution such as water, or in a physiologically compatible buffer such as Hanks' solution, Ringer's solution, or saline buffer. In certain embodiments, other components are included (e.g., components that aid solubility or serve as preservatives). In certain embodiments, the injectable suspension is prepared using a suitable liquid carrier, suspension, etc. Certain pharmaceutical compositions for injection are in unit dosage forms, e.g., ampoules or multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions, or emulsions in an oily or aqueous vehicle and may contain formulations such as suspensions, stabilizers, and / or dispersants. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents such as sesame oil and fatty oils, synthetic fatty acid esters such as ethyl oleate or triglycerides, and liposomes.
[0406] Under certain conditions, certain compounds disclosed herein function as acids. Such compounds may be illustrated or described in protonated (free acid) form or in ionized and associated with a cation (salt) form, but aqueous solutions of such compounds exist in equilibrium between these forms. For example, the phosphate bond of an oligonucleotide in aqueous solution exists in equilibrium between free acid, anionic, and salt forms. Unless otherwise indicated, the compounds disclosed herein are intended to include all such forms. Furthermore, certain oligonucleotides have several such bonds, each of which is in equilibrium. Thus, oligonucleotides in solution exist as a collection of forms, all of which are in equilibrium at multiple positions. The term “oligonucleotide” is intended to include all such forms. Illustrated structures necessarily depict a single form. Nevertheless, unless otherwise indicated, such depictions are also intended to include the corresponding forms. In this specification, structures showing a free acid of a compound followed by the term “its salt” clearly include all such forms that can be fully or partially protonated / deprotonated / associated with a cation. In certain cases, one or more specific cations are identified.
[0407] In certain embodiments, the modified oligonucleotide or oligomer compound is in an aqueous solution containing sodium. In certain embodiments, the modified oligonucleotide or oligomer compound is in an aqueous solution containing potassium. In certain embodiments, the modified oligonucleotide or oligomer compound is in PBS. In certain embodiments, the modified oligonucleotide or oligomer compound is in water. In certain such embodiments, the pH of the solution is adjusted with NaOH and / or HCl to achieve the desired pH.
[0408] In this specification, certain doses are described. Dose may be in the form of dosing units. For clarity, a dose (or dosing unit) of a modified oligonucleotide or oligomer compound in milligrams represents the mass of the modified oligonucleotide or oligomer compound in its free acid form. As described above, in aqueous solution, the free acid is in equilibrium with the anionic and salt forms. However, for the purpose of calculating doses, it is assumed that the modified oligonucleotide or oligomer compound exists as solvent-free, sodium acetate-free, anhydrous, and free acid. For example, if the modified oligonucleotide or oligomer compound is in a sodium-containing solution (e.g., physiological saline), the modified oligonucleotide or oligomer compound may be partially or completely deprotonated and associate with Na+ ions. However, even then, the mass of the proton is counted in the weight of the dose, while the mass of the Na+ ion is not counted in the weight of the dose. If the oligomer compound contains a conjugate group, the mass of the conjugate group is included in the calculation of the dose of such an oligomer compound. If the conjugate group also contains an acid, it is assumed that the conjugate group is also fully protonated for the purpose of calculating the dose.
[0409] VIII. A specific composition 1. Compound number 1205407 In a particular embodiment, compound number 1205407 is characterized as a 3-10-3MOE / cEt mixed wing gapmer conjugated to a conjugate group at the 5' end. Compound 1205407 has the sequence (5' to 3') CGCTGATTTGTCCGGG (SEQ ID NO: 12), nucleosides 1-3 have the sugar modification eek (5' to 3'), nucleosides 14-16 have the sugar modification kke, each "e" represents the 2'-MOE sugar moiety, each "k" refers to the cEt sugar moiety, and each of nucleosides 4-13 is a 2'-β-D-deoxynucleoside, between nucleosides 2 and 3, between 3 and 4, The nucleoside bond between 14 and 15 is a phosphodiester nucleoside bond, and the nucleoside bonds between nucleosides 1 and 2, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, 13 and 14, and 15 and 16 are phosphorothioate nucleoside bonds, with each cytosine being 5-methylcytosine. Compound number 1205407 has a 5'-trishexylamino-(THA)-C6GalNAc3 end cap represented by the following structure, and the phosphate group is bonded to the 5'-oxygen atom of the 5'-nucleoside.
[0410] [ka]
[0411] In certain embodiments, compound number 1205407 is represented by the following chemical notation: THA-C6-GalNAc3- m C es G eo m C ko T ds G ds A ds T ds T ds T ds G ds T ds m C ds m C ds Gko G ks G e Represented by (Sequence No. 12), in the formula, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, e is the 2'-β-D-MOE sugar moiety, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, s is a phosphorothioate nucleoside bond, o is a phosphodiester nucleoside bond.
[0412] In a particular embodiment, compound number 1205407 has the following chemical structure:
[0413] [ka]
[0414] It is represented by (Sequence ID 12), or a salt thereof.
[0415] In a particular embodiment, the sodium salt of compound number 1205407 has the following chemical structure:
[0416] [ka]
[0417] This is represented by (Sequence ID 12). In certain embodiments, compound number 1205407 exists in an anionic form.
[0418] 2. Compound number 1205408 In a particular embodiment, compound number 1205408 is characterized as a 3-10-3MOE / cEt mixed wing gapmer conjugated to a conjugate group at the 5' end. Compound 1205408 has the sequence TCGGTTGGAATTCTTT (SEQ ID NO: 13) (from 5' to 3'), nucleosides 1-3 have the sugar modification ekk (from 5' to 3'), nucleosides 14-16 have the sugar modification kke, each "e" represents the 2'-MOE sugar moiety, each "k" refers to the cEt sugar moiety, and each of nucleosides 4-13 is a 2'-β-D-deoxynucleoside, between nucleosides 2 and 3, between 3 and 4, The nucleoside bond between 14 and 15 is a phosphodiester nucleoside bond, and the nucleoside bonds between nucleosides 1 and 2, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, 13 and 14, and 15 and 16 are phosphorothioate nucleoside bonds, with each cytosine being 5-methylcytosine. Compound number 1205408 has a 5'-trishexylamino-(THA)-C6GalNAc3 end cap represented by the following structure, and the phosphate group is bonded to the 5'-oxygen atom of the 5'-nucleoside.
[0419] [ka]
[0420] In certain embodiments, compound number 1205408 is represented by the following chemical notation: THA-C6-GalNAc3-T es m C ko G ko G ds T ds T ds G ds G ds A ds A ds T ds T ds m C ds T ko T ksT e Represented by (Sequence No. 13), in the formula, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, e is the 2'-β-D-MOE sugar moiety, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, s is a phosphorothioate nucleoside bond, o is a phosphodiester nucleoside bond.
[0421] In a particular embodiment, compound number 1205408 has the following chemical structure:
[0422] [ka]
[0423] It is represented by (Sequence ID 13) or a salt thereof.
[0424] In a particular embodiment, the sodium salt of compound number 1205408 has the following chemical structure:
[0425] [ka]
[0426] This is represented by (Sequence ID 13). In certain embodiments, compound number 1205408 exists in an anionic form.
[0427] 3. Compound number 1250837 In a particular embodiment, compound number 1250837 is characterized as a 3-10-3 gapmer conjugated to a conjugate group at its 5' end. Compound 1250837 has the sequence (5' to 3') GTCGGTTGGAATTCTT (SEQ ID NO: 15), nucleosides 1-3 and 14-16 have cEt sugar modification, nucleoside 5 has 2'-OMe ribose sugar, each of nucleosides 4 and 6-13 is a 2'-β-D-deoxynucleoside, each nucleoside bond between nucleosides is a phosphorothioate nucleoside bond, and each cytosine is 5-methylcytosine. Compound number 1250837 has a 5'-trishexylamino-(THA)-C6GalNAc3 end cap, represented by the following structure, and the phosphate group is bonded to the 5'-oxygen atom of the 5'-nucleoside.
[0428] [ka]
[0429] In a particular embodiment, compound number 1250837 is represented by the following chemical notation: THA-C6-GalNAc3-G ks T ks m C ks G ds G ys T ds T ds G ds G ds A ds A ds T ds T ds m C ks T ks T k Represented by (Sequence ID 15), in the formula, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, y is the 2'-OMe ribose sugar moiety, s represents the phosphorothioate nucleoside bond.
[0430] In a particular embodiment, compound number 1250837 has the following chemical structure:
[0431] [ka]
[0432] It is represented by (Sequence ID 15), or a salt thereof.
[0433] In a particular embodiment, the sodium salt of compound number 1250837 has the following chemical structure:
[0434] [ka]
[0435] This is represented by (Sequence ID 15). In certain embodiments, compound number 1250837 exists in an anionic form.
[0436] 4. Compound number 1250851 In a particular embodiment, compound number 1250851 is characterized as a 3-10-3 gapmer conjugated to a conjugate group at its 5' end. Compound 1250851 has the sequence TCGGUTGGAATTCTTT (SEQ ID NO: 14) (from 5' to 3'), nucleosides 1-3 and 14-16 have a cEt sugar moiety, nucleoside 5 has a 2'-OMe ribose sugar, and each of nucleosides 4 and 6-13 is a 2'-β-D-deoxynucleoside, with internucleosides between nucleosides 2 and 3, between 3 and 4, and between 14 and 15. The bonds are phosphodiester nucleoside bonds, and the nucleoside bonds between nucleosides 1 and 2, 4 and 5, 5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 11, 11 and 12, 12 and 13, 13 and 14, and 15 and 16 are phosphorothioate nucleoside bonds, and each cytosine is 5-methylcytosine. Compound number 1250851 has a 5'-trishexylamino-(THA)-C6GalNAc3 end cap represented by the following structure, and the phosphate group is bonded to the 5'-oxygen atom of the 5'-nucleoside.
[0437] [ka]
[0438] In certain embodiments, compound number 1250851 is represented by the following chemical notation: THA-C6-GalNAc3-T ks m C ko G ko G ds U ys T ds G ds G ds A ds A ds T ds T ds m C ds T ko T ks T k Represented by (Sequence No. 14), in the formula, A is an adenine nucleic acid base, m C is the 5-methylcytosine nucleic acid base, G is a guanine nucleic acid base, T is a thymine nucleic acid base, U is the uracil nucleic acid base, k is the cEt sugar portion, d is the 2'-β-D-deoxyribosyl sugar moiety, y is the 2'-OMe ribose sugar moiety, s is a phosphorothioate nucleoside bond, o is a phosphodiester nucleoside bond.
[0439] In a particular embodiment, compound number 1250851 has the following chemical structure:
[0440] [ka]
[0441] It is represented by (Sequence ID 14), or a salt thereof.
[0442] In a particular embodiment, the sodium salt of compound number 1250851 has the following chemical structure:
[0443] [ka]
[0444] This is represented by (Sequence ID 14). In certain embodiments, compound number 1250851 exists in an anionic form.
[0445] VI. A specific comparative composition In certain embodiments, compound number 757456 is a comparative compound. Compound number 757456 was previously described in WO2017062816, which is incorporated herein by reference, and has the sequence CACAAACAAGCTGGTCGGTT (SEQ ID NO: 28) (from 5' to 3'), and the compound comprises a conjugate group and a modified oligonucleotide, the modified oligonucleotide being a 5-10-5MOE gapmer, the central gap segment consisting of 10 2'-β-D-deoxynucleosides, and the 5' and 3' wing segments each consisting of 5 2'-MOE modified nucleosides. Each nucleoside bond is a phosphorothioate nucleoside bond. All cytosine residues are 5-methylcytosine. Compound number 757456 has a 5'-trishexylamino-(THA)-C6GalNAc3 end cap, represented by the following structure, and the phosphate group is bonded to the 5'-oxygen atom of the 5'-nucleoside.
[0446] [ka]
[0447] In certain embodiments, compound number 568637 is a comparative compound. Compound number 568637 was previously described in WO2017062816, which is incorporated herein by reference, and has the sequence (5' to 3') CGCTGATTTGTCCGGG (SEQ ID NO: 12), and the compound consists of a modified oligonucleotide, the modified oligonucleotide being a nucleoside having a mixed sugar moiety of 16 nucleoside lengths, as described by the sugar motif eekddddddddddkke, where each "d" represents a 2'-β-D-deoxyribosyl sugar moiety, each "e" represents a 2'-MOE sugar moiety, and each "k" represents a cEt sugar moiety. Each nucleoside bond is a phosphorothioate nucleoside bond. All cytosine residues are 5-methylcytosine.
[0448] In certain embodiments, compound number 1176644 is a comparative compound. Compound number 1176644 is compound number 568637 having a 5'-trishexylamino-(THA)-C6GalNAc3 end cap. Compound number 1176644, like compound number 568637, has the sequence (from 5' to 3') CGCTGATTTGTCCGGG (SEQ ID NO: 12), and the compound comprises a modified oligonucleotide, which is a 16-nucleoside length having a mixed sugar moiety as described by the sugar motif eekddddddddddkke, where each "d" represents a 2'-β-D-deoxyribosyl sugar moiety, each "e" represents a 2'-MOE sugar moiety, and each "k" represents a cEt sugar moiety. Each nucleoside bond is a phosphorothioate nucleoside bond. All cytosine residues are 5-methylcytosine.
[0449] In certain embodiments, the compounds described herein are superior to the compounds described in WO2017062816 because they exhibit one or more improved properties, such as potency.
[0450] For example, compound number 1205407 showed improved efficacy in vivo compared to compound number 757456. As shown in Example 5, compound number 1205407 achieved 93% and 90% inhibition of AGT RNA and protein, respectively, at a dose of 2.7 mg / kg. In contrast, compound number 757456 achieved 65% and 60% inhibition of AGT RNA and protein, respectively, at a dose of 3.3 mg / kg. Therefore, compound number 1205407 is more potent than compound number 757456 in this assay. For example, as shown in Study 1 of Example 6, compound number 1205407 achieved an ED of 0.1 in liver and plasma. 50 This was achieved. In contrast, compound number 757456 showed an ED of 1.3 in the liver and plasma. 50 This was achieved. Therefore, compound number 1205407 is more potent than compound number 757456 in this assay.
[0451] For example, compound number 1205407 showed improved potency ex vivo compared to compound number 757456. As shown in Example 8, compound number 1205407 produced 0.04 nM IC ex vivo using a hepatopac system. 50 This was achieved. In contrast, compound number 757456 showed an IC50 >20 μM ex vivo. 50 It possessed [the characteristic]. Therefore, compound number 1205407 is more potent than compound number 757456 in this assay.
[0452] For example, compound number 1205407 showed improved efficacy in vitro compared to compound number 757456 or compound number 1176644. As shown in Example 7, compound number 1205407 showed 8 nM and 12 nM ICs when tested in vitro with two different primer-probe sets. 50 This was achieved. In contrast, compound number 757456 achieved IC50 at 868 nM and 709 nM under the same culture conditions in vitro. 50 This was achieved. In contrast, compound number 1176644 achieved IC50 at 35 nM and 43 nM under the same culture conditions in vitro. 50 This was achieved. Therefore, compound number 1205407 is more potent than compound number 757456 or compound number 1176644 in this assay.
[0453] For example, compound number 1205407 showed improved potency in vivo compared to compound number 757456 or compound number 1176644. As shown in Study 2 of Example 6, compound number 1205407 showed an ED of 0.11 in a transgenic mouse study. 50 and ED 0.38 75 This was achieved. In contrast, compound number 757456 is ED 2.1. 50 and ED 2.68 75 This was achieved. In contrast, compound number 1176644 has an ED of 0.38. 50 and ED 0.61 75This was achieved. Therefore, compound number 1205407 is more potent than compound number 757456 or compound number 1176644 in this assay.
[0454] Non-exclusive disclosure and incorporation by reference Each of the documents and patent publications listed herein is incorporated in their entirety by reference.
[0455] While certain compounds, compositions, and methods described herein are specifically described according to certain embodiments, the following examples are merely illustrative of the compounds described herein and are not intended to limit them. References, GenBank accession numbers, etc., listed herein are incorporated herein by reference in their entirety.
[0456] The sequence listings attached to this application identify each sequence as either "RNA" or "DNA" as appropriate, but in practice, these sequences can be modified with any combination of chemical modifications. Those skilled in the art will readily understand that the designation as "RNA" or "DNA" to describe modified oligonucleotides is, in certain cases, arbitrary. For example, an oligonucleotide containing a nucleoside with a 2'-OH sugar moiety and a thymine base may be described as DNA having a modified sugar moiety (a 2'-OH instead of one 2'-H in the DNA) or as RNA having a modified base (thymine (methylated uracil) instead of uracil in the RNA). Thus, the nucleic acid sequences provided herein, including but not limited to those in the sequence listings, are intended to encompass nucleic acids including any combination of natural or modified RNA and / or DNA, including but not limited to such nucleic acids having modified nucleic acid bases. As further examples, without limitation, oligomeric compounds having the nucleic acid base sequence "ATCGATCG" include, but are not limited to, those having the sequence "AUCGAUCG" and RNA bases such as "AUCGATCG" and several DNA bases and several RNA bases, and "AT m This includes any oligomeric compounds having such nucleic acid base sequences, including oligomeric compounds having other modified nucleic acid bases such as "CGAUCG". m C represents a cytosine base containing a methyl group at the 5-position.
[0457] Certain compounds described herein (e.g., modified oligonucleotides) have one or more chiral centers and thus give rise to enantiomers, diastereomers, and other stereoisomer configurations that can be defined with respect to absolute stereochemistry, such as as (R) or (S), as α or β in sugar anomerics, or as (D) or (L) in amino acids. Compounds provided herein that are described or described as having a particular stereoisomer configuration include only those compounds indicated. Compounds provided herein that are described or described with an undefined stereochemistry include all such possible isomers (including their stereorandom and optically pure forms) unless otherwise specified. Similarly, unless otherwise indicated, all cis and trans isomers and tautomers of the compounds herein are also included. Oligomer compounds described herein include chiralally pure or concentrated mixtures, as well as racemic mixtures. For example, oligomeric compounds having multiple phosphorothioate nucleoside interbondings include compounds in which the chirality of the phosphorothioate nucleoside interbondings is controlled or random. Unless otherwise indicated, the compounds described herein are intended to include the corresponding salt forms.
[0458] The compounds described herein include variant forms in which one or more atoms of the element shown are replaced with non-radioactive or radioactive isotopes. For example, the compounds described herein that contain a hydrogen atom are: 1 This includes all possible deuterium substitutions for each of the H hydrogen atoms. The isotopic substitutions included by the compounds herein include: 1 Instead of H 2 H or 3 H, 12 Instead of C 13 C or 14 C, 14 Instead of N 15 N, 16 Instead of O 17 O or 18 O, and 32 Instead of S 33 S,34 S, 35 S, or 36 This includes, but is not limited to, sulfur (S). In certain embodiments, non-radioactive isotope substitution can impart novel properties to oligomeric compounds that are beneficial for use as therapeutic or research tools. In certain embodiments, radioactive isotope substitution can make compounds suitable for research purposes such as imaging or for diagnostic purposes. [Examples]
[0459] The following embodiments illustrate, but do not limit, certain embodiments of the present disclosure. Furthermore, where specific embodiments are provided, the inventors intend for those specific embodiments to be generally applicable.
[0460] Example 1: Design of modified oligonucleotides complementary to human AGT nucleic acid. Modified oligonucleotides complementary to human AGT nucleic acids were designed as shown in the table below. In all the tables below, the "start site" indicates the 5' nucleoside to which the modified oligonucleotide is complementary in the target nucleic acid sequence. The "end site" indicates the 3' nucleoside to which the modified oligonucleotide is complementary in the target nucleic acid sequence. Each modified oligonucleotide listed in the table below is 100% complementary to SEQ ID NO: 1 (GENBANK accession number NM_000029.3), or SEQ ID NO: 2 (complementary to GENBANK accession number NC_000001.11 with nucleotides 230700001 to 230718000 cleaved), or both.
[0461] The modified oligonucleotides in Table 1 are 16-nucleoside lengths with mixed sugar moieties as shown in the table below, where each "d" represents a 2'-β-D-deoxyribosyl sugar moiety, each "e" represents a 2'-MOE sugar moiety, and each "k" represents a cEt sugar moiety. Each nucleoside bond is a phosphorothioate nucleoside bond. All cytosine residues are 5-methylcytosine. 568637 is a comparative compound previously described in WO2017 / 062816.
[0462] [Table 1]
[0463] All modified oligonucleotides in Tables 2-6 have a 5'-trishexylamino-(THA)-C6GalNAc3 end cap represented by the following structure, and the phosphate group is bonded to the 5'-oxygen atom of the 5'-nucleoside.
[0464] [ka]
[0465] The modified oligonucleotides in Table 2 are 16-nucleoside lengths with the mixed sugar moieties shown, where each "d" represents the 2'-β-D-deoxyribosyl sugar moiety, each "e" represents the 2'-MOE sugar moiety, and each "k" refers to the cEt sugar moiety. The nucleoside-to-nucleoside linkage motif of the gapmer is soosssssssssssos (from 5' to 3'), where each "o" represents a phosphodiester nucleoside linkage and each "s" represents a phosphorothioate nucleoside linkage. All cytosine residues are 5-methylcytosine.
[0466] [Table 2]
[0467] The modified oligonucleotides in Table 3 are 16-nucleoside lengths with the mixed sugar moieties shown, where each "d" represents the 2'-β-D-deoxyribosyl sugar moiety, each "e" represents the 2'-MOE sugar moiety, each "k" refers to the cEt sugar moiety, and each "y" refers to the 2'-OMe ribose sugar moiety. The nucleoside-to-nucleoside linkage motif of the gapmer is soosssssssssssos (from 5' to 3'), where each "o" represents a phosphodiester nucleoside linkage and each "s" represents a phosphorothioate nucleoside linkage. All cytosine residues are bold and underlined.
[0468]
number
[0469] Unless otherwise indicated, it is 5-methylcytosine, and if it is in bold and underlined, the cytosine is not methylated.
[0470] [Table 3]
[0471] The modified oligonucleotides in Table 4 are 16-nucleoside lengths with the mixed sugar motifs shown, where 'd' represents the 2'-β-D-deoxyribosyl sugar moiety, 'e' represents the 2'-MOE sugar moiety, and 'k' refers to the cEt sugar moiety. Each nucleoside bond is a phosphorothioate nucleoside bond. All cytosine residues are 5-methylcytosine.
[0472] [Table 4]
[0473] The modified oligonucleotides in Table 5 are 16-nucleoside lengths with the mixed sugar motifs shown, where 'd' represents the 2'-β-D-deoxyribosyl sugar moiety, 'e' represents the 2'-MOE sugar moiety, 'k' represents the cEt sugar moiety, and 'y' refers to the 2'-OMe ribose sugar. Each nucleoside bond is a phosphorothioate nucleoside bond. All cytosine residues are underlined in bold.
[0474]
number
[0475] Unless otherwise indicated, it is 5-methylcytosine, and if it is in bold and underlined, the cytosine is not methylated.
[0476] [Table 5]
[0477] The modified oligonucleotides in Table 6 are 5-10-5 MOE gapmers with uniform phosphorothioate nucleoside-to-nucleoside bonds. The compounds are 20 nucleoside long, with the central gap segment consisting of 10 2'-β-D-deoxynucleosides and the 5' and 3' wing segments each consisting of 5 2'-MOE modified nucleosides. Each nucleoside-to-nucleoside bond is a phosphorothioate nucleoside bond. All cytosine residues are 5-methylcytosine. 757456 is a comparative compound previously described in WO2017 / 062816.
[0478] [Table 6]
[0479] Example 2: Dose-dependent in vitro inhibition of human AGT in HepG2 cells HepG2 cells cultured at a density of 10,000 cells per well were treated by electroporation with modified oligonucleotides diluted to different concentrations as specified in the table below. After a treatment period of approximately 24 hours, AGT RNA levels were measured as described above using the human AGT primer probe set RTS3721 (as specified herein). The AGT RNA levels were normalized to human GAPDH expression levels using the primer probe set RTS104 (forward sequence GAAGGTGAAGGTCGGAGTC as specified herein as SEQ ID NO: 9, reverse sequence GAAGATGGTGATGGGATTTC as specified herein as SEQ ID NO: 10, and probe sequence CAAGCTTCCCGTTCTCAGCC as specified herein as SEQ ID NO: 11). The results are shown in the table below as the percentage of AGT inhibition compared to untreated control cells. As used herein, a value of "0" indicates that treatment with modified oligonucleotides did not inhibit AGT mRNA levels.
[0480] [Table 7]
[0481] Example 3: Tolerance of modified oligonucleotides targeting human AGT in CD-1 mice CD1 mice are a versatile mouse model frequently used for safety and efficacy studies. Mice were treated with modified oligonucleotides selected from the studies described above, and changes in the levels of various plasma chemical markers were evaluated.
[0482] treatment Male CD-1 mice aged 6-8 weeks were subcutaneously injected with 15 mg / kg of modified oligonucleotides once a week for 6 weeks (a total of 7 treatments). One group of male CD-1 mice was also injected with physiological saline. The mice were euthanized 72 hours after the final dose.
[0483] Plasma chemical markers To evaluate the effects of modified oligonucleotides on liver function, plasma levels of blood urea nitrogen (BUN), albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), and total bilirubin (TBIL) were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, NY). The results are shown in the table below.
[0484] [Table 8]
[0485] Blood samples obtained from the mouse group at week 6 were sent to IDEXX BioResearch for measurement of blood cell counts. The measured counts included red blood cell (RBC) counts, white blood cell (WBC) counts, hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and individual white blood cell counts such as monocytes (MON), neutrophils (NEU), lymphocytes (LYM), and platelets (PLT). The results are shown in the table below.
[0486] [Table 9]
[0487] The body weight of the mice was measured on day 1 and day 35, and the average body weight for each group is shown in the table below. At the end of the study, the weights of the liver, spleen, and kidneys were measured and are shown in the table below. Modified oligonucleotides that caused organ weight changes outside the expected range were excluded from further study.
[0488] [Table 10]
[0489] Example 4: Tolerance of modified oligonucleotides targeting human AGT in Sprague-Dawley rats The Sprague-Dawley rat is a multipurpose model used for safety and efficacy evaluation. Rats were treated with ionis-modified oligonucleotides from the studies described in the above examples and evaluated for changes in the levels of various plasma chemical markers.
[0490] Research 1 treatment Male Sprague-Dawley rats were maintained in a 12-hour light / dark cycle and allowed to freely feed on Purina's standard rat diet. Each group of four Sprague-Dawley rats received a subcutaneous injection of 15 mg / kg of Ionis oligonucleotide once a week for six weeks (a total of six doses). 72 hours after the last dose, the rats were euthanized, and organs, urine, and plasma were collected for further analysis.
[0491] Plasma chemical markers To evaluate the effects of ionis oligonucleotides on liver function, plasma levels of transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, NY). Plasma levels of ALT (alanine transaminase) and AST (aspartate transaminase) were measured, and the results are shown in the table below, expressed in IU / L. Plasma levels of total bilirubin (TBIL), creatinine, albumin, and blood urea nitrogen (BUN) were also measured using the same clinical chemistry analyzer, and the results are also shown in the table below.
[0492] [Table 11]
[0493] Organ weight The weights of the liver, heart, spleen, and kidneys were measured at the end of the study and are shown in the table below.
[0494] [Table 12]
[0495] renal function To evaluate the effects of ionis-modified oligonucleotides on renal function, urinary levels of total protein and creatinine were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, NY). The total protein to creatinine ratio (P / C ratio) is shown in the table below.
[0496] [Table 13]
[0497] Research 2 treatment Male Sprague-Dawley rats were maintained in a 12-hour light / dark cycle and allowed to freely feed on Purina's standard rat diet. Each group of four Sprague-Dawley rats received a subcutaneous injection of 15 mg / kg of Ionis oligonucleotide once a week for six weeks (a total of six doses). 72 hours after the last dose, the rats were euthanized, and organs, urine, and plasma were collected for further analysis.
[0498] Plasma chemical markers To evaluate the effects of ionis oligonucleotides on liver function, plasma levels of transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, NY). Plasma levels of ALT (alanine transaminase) and AST (aspartate transaminase) were measured, and the results are shown in the table below, expressed in IU / L. Plasma levels of total bilirubin (TBIL), creatinine, albumin, and blood urea nitrogen (BUN) were also measured using the same clinical chemistry analyzer, and the results are also shown in the table below.
[0499] [Table 14]
[0500] Organ weight The weights of the liver, heart, spleen, and kidneys were measured at the end of the study and are shown in the table below.
[0501] [Table 15]
[0502] renal function To evaluate the effects of ionis-modified oligonucleotides on renal function, urinary levels of total protein and creatinine were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, NY). The total protein to creatinine ratio (P / C ratio) is shown in the table below.
[0503] [Table 16]
[0504] Example 5: Activity of modified oligonucleotides complementary to human AGT in transgenic mice The AGT transgenic mouse model was developed in Dr. Curt Sigmund's laboratory by inserting a 14kb transgenic construct containing the entire human angiotensinogen gene (approximately 11.5kb) and 5'(1.2kb) and 3'(1.4kb) flanking sequences (Yang G; et al. 1994. J Biol Chem 269(51):32497-502), and was used for further testing of the modified oligonucleotides mentioned above.
[0505] treatment AGT transgenic mice were divided into groups of two. Each mouse received a 2.7 mg / kg modified oligonucleotide subcutaneous injection once a week (a total of two doses on day 0 and day 7). A group of two mice received physiological saline as a negative control. In addition, each group of two mice received a 3.3 mg / kg comparative modified oligonucleotide 757456 (a total of two doses on day 0 and day 7). The mice were sacrificed three days after the last dose (day 10). Liver and plasma were collected for analysis.
[0506] RNA and protein analysis RNA was extracted from liver tissue for real-time PCR analysis, and the amount of AGT RNA was measured using the human primer probe set RTS3721 (as described above). Results are expressed as the percentage of AGT RNA inhibition compared to a saline control, normalized to the total RNA content measured by RIBOGREEN®. In addition, plasma was extracted, and the levels of human AGT protein in the plasma were measured using an ELISA kit (Human Total Angiotensinogen Assay Kit, IBL, catalog no. 27412). Results are expressed as the percentage of AGT protein inhibition compared to a saline control.
[0507] [Table 17]
[0508] Example 6: Efficacy of modified oligonucleotides complementary to human AGT RNA in transgenic mice after multiple administrations. The modified oligonucleotides were further tested in a dose-dependent manner in the transgenic mouse model described above.
[0509] treatment AGT transgenic mice were divided into groups of two. Each mouse received two subcutaneous injections of modified oligonucleotides at the concentrations shown in the table below (on days 0 and 7). A group of four mice received PBS as a negative control. The mice were euthanized 72 hours after the last dose (day 10). Liver and plasma were collected for analysis. Compound number 757456 was added as a comparison compound in some studies.
[0510] Research 1 RNA and protein analysis RNA was extracted from liver tissue for real-time PCR analysis, and the amount of AGT RNA was measured using the human primer probe set RTS3721 (as described above). Results are expressed as the percentage of AGT RNA inhibition compared to a saline control, normalized to the total RNA content measured by RIBOGREEN®. In addition, plasma was extracted, and the levels of human AGT protein in the plasma were measured using an ELISA kit (Human Total Angiotensinogen Assay Kit, IBL, catalog no. 27412). Results are expressed as the percentage of AGT protein inhibition compared to a saline control.
[0511] [Table 18-1]
[0512] [Table 18-2]
[0513] Research 2 RNA and protein analysis RNA was extracted from liver tissue for real-time PCR analysis, and the amount of AGT RNA was measured using the human primer probe set RTS3721 (as described above). Results are expressed as the percentage of AGT RNA inhibition compared to a saline control, normalized to the total RNA content measured by RIBOGREEN®. In addition, plasma was extracted, and the levels of human AGT protein in the plasma were measured using an ELISA kit (Human Total Angiotensinogen Assay Kit, IBL, catalog no. 27412). Results are expressed as the percentage of AGT protein inhibition compared to a saline control.
[0514] [Table 19]
[0515] Research 3 RNA and protein analysis RNA was extracted from liver tissue for real-time PCR analysis, and the amount of AGT RNA was measured using the human primer probe set RTS3721 (as described above in this specification). Results are expressed as the percentage inhibition of AGT RNA compared to a saline control, normalized to the total RNA content measured by RIBOGREEN®. In addition, plasma was extracted, and human AGT protein levels in the plasma were measured using an ELISA kit (Human Total Angiotensinogen Assay Kit, IBL, catalog no. 27412). Results are expressed as the percentage inhibition of AGT protein compared to a saline control. Where used herein, a value of "0" indicates that treatment with modified oligonucleotides did not inhibit AGT levels.
[0516] [Table 20]
[0517] Example 7: Dose-dependent in vitro inhibition of human AGT in transgenic mouse hepatocytes The transgenic AGT mouse model described above was used in this study. The modified oligonucleotides described in the above study were tested at various doses to inhibit AGT RNA in primary mouse hepatocytes extracted from these transgenic mice.
[0518] Primary mouse transgenic hepatocytes were seeded at a density of 20,000 cells per well and treated by free uptake with modified oligonucleotides diluted to different concentrations, as shown in the table below. After overnight incubation, AGT RNA levels were measured using the human AGT primer probe set RTS3721 (forward sequence CCCTGATGGGAGCCAGTGT as specified herein as SEQ ID NO: 3, reverse sequence AGCAGGGAGAAGCCCTTCA as specified herein as SEQ ID NO: 4, probe sequence CCCTGGCTTTCAACACCTACGTCCACT as specified herein as SEQ ID NO: 5). In addition, human AGT RNA levels were measured using a second human AGT primer set RTS4039 (forward sequence GGACAGGTGGAGGGTCTCA as specified herein as SEQ ID NO: 6, reverse sequence AGATCCTTGCAGCACCAGTTG as specified herein as SEQ ID NO: 7, probe sequence ATGAAGAAACTATCTCCCCGGACCATCCA as specified herein as SEQ ID NO: 8). AGT RNA levels were normalized to total RNA content as measured by RIBOGREEN®. The results are shown in the table below as the percentage inhibition of AGT compared to untreated control cells. Where used herein, a value of "0" indicates that treatment with the modified oligonucleotide did not inhibit AGT mRNA levels. The median inhibitory concentration (IC) of each modified oligonucleotide is shown. 50 ) is also shown. IC 50This was calculated using a nonlinear regression method with a four-parameter variable slope method for log(inhibitor) versus response, with the lower and upper limits fixed at 0 and 100, respectively (Prism).
[0519] [Table 21]
[0520] [Table 22]
[0521] Example 8: Dose-dependent ex vivo inhibition of human AGT with HepatoPac® The HepatoPac® kit is a commercially available liver model system from BIOIVT consisting of micropatterned hepatocyte "islands" co-cultured with supporting stromal cells. 96-well HepatoPac plates were equilibrated in fresh maintenance medium at 37°C and 10% CO2 for 48 hours prior to treatment. Modified oligonucleotides were diluted in maintenance medium at the concentrations listed in the table below for 48 hours. After 48 hours, the medium was replaced with fresh maintenance medium without additional oligonucleotides. Cell lysates were collected 96 hours after oligonucleotide addition and analyzed by RT-PCR using the primer-probe set RTS3721 (as described above). The results are shown in the table below as the percentage inhibition of AGT compared to untreated control cells. Where used herein, a value of "0" indicates that treatment with modified oligonucleotides did not inhibit AGT mRNA levels. IC 50 The curve was calculated using variable gradient 4-parameter logistic regression in Prism, with the lower and upper limits of the curve set to 5 and 100, respectively.
[0522] [Table 23]
[0523] Example 9: Effects of modified oligonucleotides targeting human AGT in cynomolgus monkeys Cynomolgus monkeys were treated with modified oligonucleotides selected from the studies described in the above examples.
[0524] treatment Prior to the study, the monkeys were isolated, followed by an acclimatization period in which the animals were observed daily for their general health. The monkeys were 2–4 years old and weighed 2–4 kg. Nine groups of four randomly assigned male cynomolgus monkeys were each subcutaneously injected with either ionis oligonucleotide or saline solution, rotating clockwise between four different sites on the back. Following loading doses on days 1, 4, and 8, the monkeys were administered 20 mg / kg of ionis oligonucleotide once a week (days 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85). A control group of four cynomolgus monkeys was injected with 0.9% saline solution in a similar manner.
[0525] During the study period, the monkeys were observed at least once a day for signs of illness or distress. Animals showing signs of severe weakness or toxicity, especially those deemed to be on the verge of death, were euthanized as soon as possible for humane reasons, in consultation with the attending veterinarian. Planned euthanasia of the animals was carried out on day 87, approximately 48 hours after the last dose, by total blood collection under deep anesthesia. The protocols described in the examples were approved by the Animal Care Committee (IACUC).
[0526] Body weight and organ weight measurement Body weight and organ weights were measured to assess the effects of ionis oligonucleotides on the overall health of the animals. Final body weight was measured before autopsy. Organ weights were also measured, and all weight measurements are shown in the table below.
[0527] [Table 24]
[0528] Renal function and hepatic function To evaluate the effects of ionis oligonucleotides on liver and kidney function, blood samples were collected from all study groups on day 87. Monkeys were fasted overnight before blood collection. Blood was collected in anticoagulant-free tubing for serum separation. The tubing was kept at room temperature for at least 90 minutes, then centrifuged at 3000 rpm for 10 minutes to obtain serum. Levels of various liver function markers were measured using a Toshiba 200FR NEO chemical analyzer (Toshiba Co., Japan). Plasma levels of blood urea nitrogen (BUN), creatinine (CREA), total protein (TP), albumin (ALB), globulin (GLO), calculated albumin / globulin (A / G) ratio, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) were measured, and the results are shown in the table below.
[0529] [Table 25]
[0530] Pro-inflammatory protein analysis To evaluate the arbitrary inflammatory effects of ionis-modified oligonucleotides in cynomolgus monkeys, blood samples were collected for analysis. The monkeys were fasted overnight before blood collection. On day 85 (before administration and 24 hours after administration), approximately 0.8 mL of blood was collected from each animal in a tube without anticoagulants for serum separation. The tubes were kept at room temperature for at least 90 minutes, and then centrifuged at 3,000 rpm at room temperature for 10 minutes to obtain serum. Complement C3 was measured using a Toshiba 120FR NEO chemical analyzer (Toshiba Co., Japan). Another inflammatory marker, C-reactive protein (CRP), was tested along with the clinical chemistry parameters tested for liver function described above.
[0531] [Table 26]
[0532] Hematological tests To evaluate any effects of ionis-modified oligonucleotides on blood parameters in cynomolgus monkeys, approximately 0.5 mL of blood samples were collected from each study animal available on day 87. Samples were collected in tubes containing K2-EDTA. Samples were analyzed using an ADVIA2120i blood analyzer (Siemens, USA) for red blood cell (RBC) count, hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count (PLT), white blood cell (WBC) count, and individual white blood cell counts such as monocytes (MON), neutrophils (NEU), and lymphocytes (LYM).
[0533] [Table 27]
[0534] urine analysis Food was removed overnight the day before fresh urine collection, but water was supplied. On day 87 (first thing in the morning), fresh urine samples for urinalysis and urinalysis were collected from all animals using a clean cage pan on wet ice. Urine analysis / urinalysis parameters included creatinine (UCRE), protein / creatinine (P / C) ratio, microprotein (UTP), and urinary microalbumin (UALB), measured using a Toshiba 120FR automated chemical analyzer (Toshiba Co., Japan).
[0535] [Table 28]
Claims
1. The chemical structure: 【Chemistry 1】 An oligomeric compound according to (SEQ ID NO: 12), or a salt thereof.
2. The chemical structure: 【Chemistry 2】 An oligomeric compound according to (SEQ ID NO: 12).
3. The following chemical notations: m C es G eo m C ko T ds G ds A ds T ds T ds T ds G ds T ds m C ds m C ds G ko G ks G e An oligomeric compound comprising a modified oligonucleotide according to (SEQ ID NO: 12), wherein A is an adenine nucleobase, m C is a 5-methylcytosine nucleobase; G is a guanine nucleobase; T is a thymine nucleobase, e is a 2'-β-D-MOE sugar moiety; k is a cEt sugar moiety; d is a 2'-β-D-deoxyribosyl sugar moiety; s is a phosphorothioate internucleoside linkage; o is a phosphodiester internucleoside linkage; The oligomeric compound.
4. 1. An oligomeric compound comprising a modified oligonucleotide consisting of 14 to 30 linked nucleosides and having a nucleobase sequence comprising at least 14, at least 15, or at least 16 consecutive nucleobases of the nucleobase sequence of SEQ ID NO:12, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage, and at least one, at least two, or at least three phosphodiester internucleoside linkages.
5. 1. An oligomeric compound comprising a modified oligonucleotide consisting of 14 to 30 linked nucleosides and having a nucleobase sequence comprising at least 14, at least 15, or at least 16 contiguous nucleobases complementary to an equal length portion of nucleobases 2046 to 2061 of SEQ ID NO:1, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage, and at least one, at least two, or at least three phosphodiester internucleoside linkages.
6. The modified oligonucleotide comprises at least one bicyclic sugar moiety having a 4'-2' bridge, the 4'-2' bridge being -CH 2 -O- and -CH(CH 3 6. The oligomeric compound according to claim 4 or 5, wherein the alkyl group is selected from the group consisting of --O--.
7. The oligomeric compound of any one of claims 4 to 6, wherein the modified oligonucleotide comprises at least one non-bicyclic modified sugar moiety, wherein the non-bicyclic modified sugar moiety is a 2'-MOE sugar moiety or a 2'-OMe sugar moiety.
8. 8. The oligomeric compound of any one of claims 4 to 7, wherein the modified oligonucleotide comprises at least one sugar surrogate, the sugar surrogate being any of morpholino, modified morpholino, peptide nucleic acid (PNA), tetrahydropyran (THP), and fluorohexitol nucleic acid (F-HNA).
9. The oligomeric compound according to any one of claims 4 to 8, wherein the modified oligonucleotide is a gapmer.
10. The modified oligonucleotide has a sugar motif, the sugar motif being a 5' region consisting of 1 to 6 linked 5' region nucleosides; a central region consisting of 6 to 10 linked central region nucleosides; a 3' region consisting of 1 to 6 linked 3' region nucleosides; Including, each of the 5' region nucleosides and each of the 3' region nucleosides comprises a modified sugar moiety and at least six of the central region nucleosides comprise a 2'-β-D-deoxyribosyl sugar moiety; a 5' region consisting of 1 to 6 linked 5' region nucleosides; a central region consisting of 6 to 10 linked central region nucleosides; a 3' region consisting of 1 to 6 linked 3' region nucleosides; Including, each of the 5' region nucleosides and each of the 3' region nucleosides comprises a modified sugar moiety and each of the central region nucleosides comprises a 2'-deoxyribosyl sugar moiety; a 5' region consisting of three linked 5' region nucleosides; a central region consisting of 10 linked central region nucleosides; a 3' region consisting of three linked 3' region nucleosides; Including, each of the 5' region nucleosides and each of the 3' region nucleosides comprises a 2'-MOE or a cEt modified sugar moiety, and each of the central region nucleosides comprises a 2'-β-D-deoxyribosyl sugar moiety; or a 5' region consisting of three linked 5' region nucleosides; a central region consisting of 10 linked central region nucleosides; a 3' region consisting of three linked 3' region nucleosides; Including, each of the 5' region nucleosides and each of the 3' region nucleosides comprises a 2'-MOE or a cEt modified sugar moiety, and at least six of the central region nucleosides comprise a 2'-β-D-deoxyribosyl sugar moiety; 10. The oligomeric compound of claim 9.
11. 11. The oligomeric compound of any one of claims 4 to 10, wherein the modified oligonucleotide has a sugar motif (5' to 3') selected from eekdddddddddddddkke, ekkddddddddddddddkke, kkkdyddddddddddddkkk, kkkddyddddddddddddkk, kkkdddyddddddddddkkk, kkkdddyddddddddddkkk, kkkdddddyddddddddddkkk, or eeeeeeddddddddddddddddeeee, wherein "e" represents a 2'-MOE sugar moiety, "k" represents a cEt sugar moiety, "d" represents a 2'-β-D-deoxyribosyl sugar moiety and "y" represents a 2'-OMe sugar moiety.
12. The modified oligonucleotide comprises at least one modified internucleoside linkage; each internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage; at least one internucleoside linkage is a phosphorothioate internucleoside linkage; The modified oligonucleotide contains at least one phosphodiester internucleoside linkage; each internucleoside linkage is either a phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage; each internucleoside linkage is a phosphorothioate internucleoside linkage; and / or the modified oligonucleotide has a soossssssssssss internucleoside linkage motif, s is a phosphorothioate internucleoside linkage; o is a phosphodiester internucleoside linkage; The oligomeric compound according to any one of claims 4 to 11.
13. The oligomeric compound according to any one of claims 4 to 12, wherein the modified oligonucleotide comprises at least one modified nucleobase, said modified nucleobase being 5-methylcytosine.
14. 14. The oligomeric compound of any one of claims 4 to 13, wherein the modified oligonucleotide consists of 14-30, 14-22, 14-20, 14-18, 14-20, 15-17, 15-25, 16-20, or 16 linked nucleosides.
15. comprising a conjugate group, the conjugate group comprises a GalNAc cluster containing 1-3 GalNAc ligands; the conjugate group comprises a conjugate linker consisting of a single bond; The conjugate group comprises a cleavable linker; the conjugate group comprises a conjugate linker comprising 1 to 3 linker nucleosides; the conjugate group is attached to a modified oligonucleotide at the 5'-nucleoside of said modified oligonucleotide; and / or the conjugate group is attached to a modified oligonucleotide at the 3'-nucleoside of said modified oligonucleotide; The oligomeric compound according to any one of claims 4 to 14.
16. The oligomeric compound according to any one of claims 4 to 15, wherein the oligomeric compound is a single-stranded oligomeric compound.
17. The oligomeric compound according to any one of claims 4 to 16, which consists of said modified oligonucleotide.
18. 2. The oligomeric compound of claim 1 which is a sodium or potassium salt.
19. The oligomeric compound of claim 3 comprising a modified oligonucleotide covalently attached to a conjugate group.
20. An oligomeric duplex comprising an oligomeric compound according to any one of claims 1 to 19.
21. 21. An antisense compound comprising or consisting of an oligomeric compound according to any one of claims 1 to 19 or an oligomeric duplex according to claim 20.
22. 20. A chirally enriched population of oligomeric compounds according to any one of claims 1 to 3, 18 or 19, wherein the population is enriched for compounds containing at least one particular phosphorothioate internucleoside linkage having a particular stereochemical configuration.
23. the population is enriched for compounds that contain at least one particular phosphorothioate internucleoside linkage having an (Sp) configuration; the population is enriched for compounds that contain at least one particular phosphorothioate internucleoside linkage having an (Rp) configuration; the population is enriched for compounds having a particular independently selected stereochemical configuration at each phosphorothioate internucleoside linkage; the population is enriched for compounds having an (Sp) configuration at each phosphorothioate internucleoside linkage, or for modified oligonucleotides having an (Rp) configuration at each phosphorothioate internucleoside linkage; the population is enriched for compounds having the (Rp) configuration at one particular phosphorothioate internucleoside linkage and the (Sp) configuration at each of the remaining phosphorothioate internucleoside linkages; the population is enriched for compounds having at least three consecutive phosphorothioate internucleoside linkages in the 5' to 3' orientation in the Sp, Sp, and Rp configurations; 23. The chirally enriched population of claim 22.
24. 20. The population of oligomeric compounds of any one of claims 1 to 3, 18 or 19, wherein all of the phosphorothioate internucleoside linkages of the oligomeric compounds are stereorandom.
25. 25. A pharmaceutical composition comprising an oligomeric compound according to any one of claims 1-3, 18 or 19, an oligomeric duplex according to claim 20, an antisense compound according to claim 21, or a population according to any one of claims 22-24, and a pharma- ceutically acceptable carrier or diluent.
26. 26. The pharmaceutical composition of claim 25, wherein the pharma- ceutically acceptable diluent is water or PBS.
27. 25. A pharmaceutical composition comprising an oligomeric compound according to any one of claims 1 to 19, an oligomeric duplex according to claim 20, an antisense compound according to claim 21, or a population according to any one of claims 22 to 24.
28. 28. A pharmaceutical composition for treating a disease associated with the renin-angiotensin-aldosterone system (RAAS) pathway comprising an oligomeric compound according to any one of claims 1-19, an oligomeric duplex according to claim 20, an antisense compound according to claim 21, a population according to any one of claims 22-24, or a pharmaceutical composition according to any one of claims 25-27.
29. 29. The pharmaceutical composition of claim 28, wherein the disease is a cardiovascular disease.
30. 30. The pharmaceutical composition of claim 28 or 29, wherein the disease is selected from hypertension, resistant hypertension, Marfan syndrome, heart failure, kidney disease, obesity, metabolic syndrome, NASH, and NAFLD.
31. The pharmaceutical composition of any one of claims 28 to 30, wherein at least one symptom or characteristic of the disease is ameliorated.
32. 32. The pharmaceutical composition of claim 31, wherein the condition or characteristic is any one of hypertension, hypertensive emergency (i.e., malignant hypertension), stroke, pre-eclampsia, vascular aneurysm, abdominal aneurysm, peripheral arterial disease, organ injury, or pulmonary arterial hypertension.
33. The pharmaceutical composition according to any one of claims 27 to 32, which is administered systemically.
34. The pharmaceutical composition according to any one of claims 27 to 33, which is administered subcutaneously or intramuscularly.
35. A pharmaceutical composition for reducing AGT expression in a cell comprising an oligomeric compound according to any one of claims 1 to 19, an oligomeric duplex according to claim 20, an antisense compound according to claim 21, a population according to any one of claims 22 to 24, or a pharmaceutical composition according to any one of claims 25 to 27.
36. 36. The pharmaceutical composition according to claim 35, wherein the level of AGT RNA is reduced.
37. 36. The pharmaceutical composition according to claim 35, wherein the level of AGT protein is reduced.
